A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Phase: PHASE2
Conditions: Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
Sponsor: Al B. Benson, III, MD

  
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
Protocol Title 
 
A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of 
Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma.  
Big Ten Cancer Research Consortium: BTCRC-GI15-015 
 
Sponsor Investigator 
Al B. Benson, III, MD 
Robert H. Lurie Comprehensive Cancer Center of Northwestern University 
 
Co-Investigators 
Mary Mulcahy, MD 
Sheetal Kircher, MD 
 
Statistician 
Hui Zhang, PhD 
 
Trial Management Provided by  
Big Ten CRC Administrative Headquarters at Hoosier Cancer Research Network, Inc. 
500 N. Meridian, Suite 100 
Indianapolis, IN 46204 
 
Trial Supported by  
Celgene Corporation 
(AX-CL-GAS-PI-006239) 
 
Investigational New Drug (IND) #  
Exempted by FDA on 05JUN2017 
 
 
 
Initial Protocol Version Date: 05MAY2017 (revised) 
 
Protocol Amendment Version Date:  
29AUG2019  
15FEB2021(current) 
 
 

Big Ten Cancer Research Consortium 
 
 
 Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 2 of 45 
PROTOCOL SIGNATURE PAGE 
 
A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of 
Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma.  
Big Ten Cancer Research Consortium: BTCRC-GI15-015 
 
 
VERSION DATE:  15FEB2021 
I confirm I have read this protocol, I understand it, and I will work according to this protocol and to the 
ethical principles stated in the latest version of the Declaration of Helsinki, the applicable guidelines for 
good clinical practices, whichever provides the greater protection of the individual. I will accept the 
monitor’s overseeing of the study. I will promptly submit the protocol to applicable ethical review 
board(s). 
 
 
 
 
____________________________________ 
________________________ 
 Signature of Site Investigator 
 
 
  
 Date 
 
 
____________________________________ 
 Site Investigator Name (printed) 
 
 
____________________________________ 
 Site Investigator Title 
 
 
____________________________________ 
 Name of Facility 
 
 
____________________________________ 
 Location of Facility (City and State) 
 
 
 
PLEASE EMAIL COMPLETED FORM TO BIG TEN CRC ADMINISTRATIVE 
HEADQUARTERS 
 
 
 

Big Ten Cancer Research Consortium 
 
 
 Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 3 of 45 
SYNOPSIS 
TITLE 
A Phase II Study of FOLFOX combined with Nab-Paclitaxel 
(FOLFOX-A) in the Treatment of Metastatic or Advanced 
Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. 
Big Ten Cancer Research Consortium: BTCRC-GI15-015 
SHORT TITLE 
FOLFOX-A in the Treatment of Metastatic or Advanced 
Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma 
PHASE  
II 
OBJECTIVES 
Primary Objective: 
 To estimate the overall objective response rate (CR+PR) of 
FOLFOX combined with nab-paclitaxel (FOLFOX-A) in 
patients with advanced gastric, gastroesophageal junction 
adenocarcinoma. 
Secondary Objectives: 
 To evaluate clinical efficacy by assessment of median OS, PFS, 
TTP as well as best ORR and disease control rate (DCR) 
 Describe the safety and toxicity profile of the combination of 
nab-paclitaxel and FOLFOX in this population 
KEY ELIGIBILITY 
CRITERIA  
Inclusion: 
1. Histologically-confirmed advanced or metastatic unresectable 
gastric carcinoma, or adenocarcinoma of the gastroesophageal 
junction. 
2. Prior neoadjuvant or adjuvant chemotherapy, hormonal therapy, 
immunotherapy, radiation or chemoradiotherapy must have been 
completed at least 6 months prior to documented recurrence or 
metastatic disease. NOTE: patients must not have received 
previous systemic treatment for metastatic disease. 
3. Evaluable disease according to RECIST v1.1 for solid tumors, 
within 28 days prior to registration. 
4. Demonstrate adequate organ function as described below. 
a. Bilirubin < 1.5 mg/dL 
b. Patients must have adequate liver function: AST and ALT < 2.5 
 upper limit of normal, alkaline phosphatase < 2.5  upper 
limit of normal, unless bone or liver metastasis is present (≤5  
upper limit of normal). 
c. Patients must have adequate bone marrow function: Platelets 
>100,000 cells/mm3 (transfusion independent, defined as not 
receiving platelet transfusions within 7 days prior to laboratory 
sample), Hemoglobin > 9.0 g/dL and ANC > 1,500 cells/mm3. 
d. Patients must have adequate renal function: creatinine ≤1.5 
mg/dL or creatinine clearance ≥60 mL/min is recommended; 
however, institutional norms are acceptable. 
 
Exclusion: 
1. Her-2 positive gastric tumor

Big Ten Cancer Research Consortium 
 
 
 Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 4 of 45 
2. Preexisting peripheral neuropathy is not allowed from any cause. 
3. Known history of Human Immunodeficiency Virus (HIV) or 
Hepatitis C (baseline testing is not required) 
4. Patients with active sepsis or pneumonitis 
5. Known hypersensitivity to fluorouracil (5-FU), oxaliplatin, or 
other platinum agents. 
6. Known hypersensitivity to nab-paclitaxel or any of its excipients. 
7. History of slowly progressive dyspnea and unproductive cough, 
or pulmonary conditions such as sarcoidosis, silicosis, idiopathic 
pulmonary fibrosis, hypersensitivity pneumonitis or multiple 
allergies. See section 6.5.1. 
8. Has known dihydropyrimidine dehydrogenase deficiency (DPD) 
deficiency (testing not required) 
9. Ongoing or active infection requiring systemic treatment (must be 
afebrile for ≥ 48 hours prior to study registration) 
10. Uncontrolled intercurrent illness including, but not limited to any 
of the following: 
a. Symptomatic congestive heart failure 
b. Unstable angina pectoris 
c. Cardiac arrhythmia
STATISTICAL 
CONSIDERATIONS 
The primary endpoint will be the objective response rate (partial or 
complete response). A Simon (1989), optimal two-stage design 
will be employed. A 5% response rate precludes further study 
whereas a 20% response rate would indicate that further 
investigation of the treatment is warranted (i.e., P0=0.05 and 
P1=0.20 in the Simon terminology). Using α and β errors of 0.10 
and 0.10, respectively, 12 patients will be enrolled in the first stage 
and if no responses are observed, the trial will be terminated. 
Otherwise, an additional 27 patients will be enrolled in the second 
stage and if ≤ 3 responses are observed among the 39 patients, the 
agent will not be considered worthy of further testing; whereas, if 4 
or more responses are observed the drug will be considered 
sufficiently active to justify further study. This design has 90% 
power under the alternative hypothesis and provides a 54% 
probability of early stopping if the true response rate is only 5%.
TOTAL  
NUMBER OF 
SUBJECTS 
 39 
ESTIMATED 
ENROLLMENT 
PERIOD 
18 months 
ESTIMATED 
STUDY DURATION  
24 months 
 
 

Big Ten Cancer Research Consortium 
 
 
 Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 5 of 45 
TABLE OF CONTENTS 
 
SYNOPSIS .................................................................................................................................................. 3 
Schema ........................................................................................................................................................ 7 
1. 
Background and Rationale .................................................................................................................. 8 
 
Gastric Cancer- Disease Overview ............................................................................................. 8 
 
Treatment of Gastric Cancer ....................................................................................................... 8 
 
Role of Nab-Paclitaxel ................................................................................................................ 9 
 
Rationale for the Current Study and Dose Selection ................................................................ 10 
2. 
Study Objectives and Endpoints ....................................................................................................... 10 
 
Objectives ................................................................................................................................. 10 
 
Endpoints .................................................................................................................................. 10 
3. 
Eligibility Criteria ............................................................................................................................. 11 
 
Inclusion Criteria ...................................................................................................................... 11 
 
Exclusion Criteria ..................................................................................................................... 12 
4. 
Subject Registration .......................................................................................................................... 13 
5. 
Treatment Plan .................................................................................................................................. 13 
 
Pre-medication and Hydration .................................................................................................. 13 
 
Dose Calculations ..................................................................................................................... 13 
 
Treatment Administration ......................................................................................................... 14 
 
Concomitant Medications ......................................................................................................... 15 
 
Supportive Care ........................................................................................................................ 15 
6. 
Toxicities and Dose Delays/Dose Modifications .............................................................................. 16 
 
Dose Delays/Dose Modifications ............................................................................................. 16 
 
Dose Levels for Dose Reductions ............................................................................................. 17 
 
Hematologic Toxicities ............................................................................................................. 17 
 
Neuropathy ................................................................................................................................ 18 
 
Interstitial Pneumonitis ............................................................................................................. 19 
 
Sepsis: ....................................................................................................................................... 19 
 
Protocol Therapy Discontinuation ............................................................................................ 20 
 
Study Withdrawal ..................................................................................................................... 20 
7. 
Study Calendar & Evaluations .......................................................................................................... 21 
 
Safety Follow-up Visit Evaluations .......................................................................................... 23 
 
Long Term Follow-up Evaluations ........................................................................................... 23 
8. 
Biospecimen Studies ......................................................................................................................... 23 
 
Correlative studies .................................................................................................................... 23 
 
Samples for future studies ......................................................................................................... 23 
 
Confidentiality of Biospecimens ............................................................................................... 23 
9. 
Criteria for Disease Evaluation ......................................................................................................... 24 
 
Measurable Disease .................................................................................................................. 24 
 
Non-measurable Lesions ........................................................................................................... 24 
 
Target Lesions ........................................................................................................................... 24 
 
Non-target Lesions .................................................................................................................... 24 
 
Evaluation of Target Lesions .................................................................................................... 25 
 
Evaluation of Non-Target Lesions ............................................................................................ 25 
 
Evaluation of Best Overall Response ....................................................................................... 26 

Big Ten Cancer Research Consortium 
 
 
 Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 6 of 45 
10. Drug Information .............................................................................................................................. 26 
 
Nab-Paclitaxel (Abraxane®)...................................................................................................... 26 
 
5-Fluorouracil (5-FU, Fluorouracil, Adrucil) ........................................................................... 28 
 
Leucovorin (Leucovorin Calcium, Folinic Acid, Citrovorum Factor, N 5- 
Formyltetrahydrofolate, 5-Formyl-FH4) .............................................................................................. 29 
 
Oxaliplatin (Eloxatin) ............................................................................................................... 30 
11. Adverse Events ................................................................................................................................. 32 
 
Definitions................................................................................................................................. 32 
 
Reporting................................................................................................................................... 34 
 
IND Safety Reports Unrelated to this Trial .............................................................................. 37 
12. Statistical Methods ............................................................................................................................ 37 
 
Endpoints .................................................................................................................................. 37 
 
Sample Size and Accrual .......................................................................................................... 38 
 
Analysis Datasets ...................................................................................................................... 38 
 
Assessment of Safety ................................................................................................................ 39 
 
Data Analysis Plan. ................................................................................................................... 39 
13. Trial Management ............................................................................................................................. 40 
 
Data and Safety Monitoring ...................................................................................................... 40 
 
Data Quality Oversight Activities ............................................................................................. 41 
 
Amendments ............................................................................................................................. 41 
 
Compliance with Trial Registration and Results Posting Requirements .................................. 41 
14. Data Handling and Record Keeping ................................................................................................. 42 
 
Data Management ..................................................................................................................... 42 
 
Case Report Forms and Submission ......................................................................................... 42 
 
Record Retention ...................................................................................................................... 42 
 
Confidentiality .......................................................................................................................... 42 
15. Ethics................................................................................................................................................. 43 
 
Institutional Review Board (IRB) Approval ............................................................................. 43 
 
Ethical Conduct of the Study .................................................................................................... 43 
 
Informed Consent Process ........................................................................................................ 43 
16. References ......................................................................................................................................... 44 

Big Ten Cancer Research Consortium 
 
 
 Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 7 of 45 
SCHEMA 
 
A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of 
Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma.  
Big Ten Cancer Research Consortium: BTCRC-GI15-015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Line Treatment of Patients with Advanced or Unresectable 
Gastric/Gastroesophageal Adenocarcinoma (n=39) 
Stage I (N= 12) 
Days 1 and 15 (cycle=28 days) 

Nab-paclitaxel 150 mg/m2 

Oxaliplatin 85 mg/m2 

Leucovorin 400 mg/m2 

5-FU 2400 mg/m2 over 46-48 hrs 
≥ 1 response observed 
0 responses observed 
Terminate Study 
Stage II (N= 27) 
Every 14 days 

Nab-paclitaxel 150 mg/m2 

Oxaliplatin 85 mg/m2 

Leucovorin 400 mg/m2 

5-FU 2400 mg/m2 over 46-48 hrs 
≥ 4 responses observed 
≤ 3 responses observed 
Terminate Study
Treat until disease 
progression or 
unacceptable toxicity 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 8 of 45 
1. 
BACKGROUND AND RATIONALE 
 
Gastric Cancer- Disease Overview 
Gastric Cancer is one of the most common types of cancer, ranking third among the most prevalent 
malignancies. [1] Despite the introduction of new drugs and treatment strategies, the clinical outcomes 
for this malignancy remains poor, with a 5-year survival rate of only about 20 percent (all stages).  The 
primary curative option in this clinical scenario is surgical excision.  Unfortunately, most patients are 
diagnosed with advanced disease, making surgical resection either not feasible or available with purely 
palliative intent.  While earlier diagnosis would help to improve outcomes for patients with gastric 
cancers, a significant unmet medical need exists because no effective therapy has yet been identified.  
The current standard chemotherapy regimens appear to have a marginal survival benefit. Hence newer 
agents and combinations are desperately needed. 
 
Chemotherapy likely provides some benefit for patients with advanced gastric/gastroesophageal junction 
(GEJ) cancers. In a recent meta-analysis, it was concluded that chemotherapy produces superior survival 
as compared with best supportive care. [2] It was also concluded that combination chemotherapy 
(usually using a fluoropyrimidine, a taxane, an anthracycline, and a platinum agent) improves survival 
as compared with single-agent chemotherapy, but with additional toxicity. [3] Nonetheless, the 
prognosis for patients with advanced gastric cancer is dismal, with median survival typically being less 
than 10 months. [4] 
 
Treatment of Gastric Cancer 
A number of validated doublet and triplet chemotherapy combinations are available as first line therapy, 
although there is no consensus as to the best regimen for initial chemotherapy of advanced 
esophagogastric cancer. In general, combination chemotherapy regimens provide higher response rates 
than do single agents, but this translates into only modestly longer durations of disease control and 
survival that are measured in weeks to a few months. In randomized trials, the ECF (epirubicin, 
cisplatin, infusional 5-fluorouracil [5-FU]) and DCF ([TCF] docetaxel, cisplatin, infusional 5-FU) 
combinations have emerged as standard regimens for first-line treatment, unfortunately however adding 
increased toxicity and possible worsening patients’ quality of life (QOL).  Hence better-tolerated 
chemotherapy alternatives that can provide higher efficacy and better tolerability are urgently needed. 
 
Platinum–taxane combinations like DCF are an established regimen for treatment in advanced gastric / 
GEJ adenocarcinoma. Docetaxel plus cisplatin and 5-FU (the DCF or TCF regimen), was compared with 
cisplatin and 5-FU alone in a multi-national TAX-325 trial that enrolled 457 patients with 
chemotherapy-naïve advanced gastric cancer. Patients received either 21-day cycles of cisplatin (75 
mg/m2 on day 1) plus infusional 5-FU (750 mg/m2 daily, days 1 to 5) and docetaxel (75 mg/m2 on day 
1), or 28-day cycles of cisplatin (100 mg/m2 on day 1) plus infusional 5-FU (1000 mg/m2 per day days 1 
to 5). The group receiving docetaxel did significantly better in terms of response rates (37 versus 25 
percent), time to progression (TTP, 5.6 versus 3.7 months), and two-year survival (18 versus 9 percent). 
Although the incidence of grade 3 or 4 diarrhea (20 versus 8 percent) and neutropenia (30 versus 14 
percent) was higher with triple therapy, rates of any grade 3 or 4 toxicity during therapy were high in 
both groups (81 and 75 percent, respectively). [5] 
 
The support of oxaliplatin as an anchor drug in advanced gastric cancer comes from extensive data that 
suggest that oxaliplatin is at least as effective as cisplatin in combination regimens for patients with 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 9 of 45 
advanced gastric and esophagogastric cancer. A meta-analysis of the Randomised ECF for Advanced 
and Locally Advanced Esophagogastric Cancer-2 (REAL-2) study in conjunction with two other 
randomized phase II trials showed that oxaliplatin was associated with significant improvements in PFS 
(HR 0.88, 95% I 0.80-0.98) and overall survival (HR for death 0.88, 95% CI 0.78-0.99), and fewer 
neutropenia, anemia, alopecia, and thromboembolic events, but more neurotoxicity and diarrhea. [6] [7] 
[8] Although oxaliplatin has been used in the backbone chemotherapy in a number of trials in 
combination with other cytotoxic agents in advanced gastric/esophagogastric tumors, overall there was 
not a significant improvement in efficacy. 
 
The poor prognosis for patients diagnosed with metastatic gastric/esophagogastric cancer suggests the 
need for 1) a more effective agent to improve and expand treatment options and 2) to create a better-
tolerated alternative to those standard regimens currently used as first line regimens. 
 
Role of Nab-Paclitaxel 
Paclitaxel is a hydrophobic molecule and is dissolved in a solvent, cremophor EL (CrEL), which has 
been associated with significant risk of hypersensitivity reactions and neuropathy. Moreover, CrEL is 
also known to impair free drug delivery to the tumor, limiting clinical effectiveness of paclitaxel [9]. 
Nab-paclitaxel (Abraxane®, Celgene, Summit, NJ) was developed as a solvent-free, albumin-bound 
colloidal formulation of paclitaxel for intravenous (IV) use allowing for shorter infusion time without 
pre-medications or specialized infusion sets. Comparative intra-tumoral and anti-tumoral activity of nab-
paclitaxel has been demonstrated to be greater than CrEL-paclitaxel in multiple tumor types using 
preclinical models [10, 11]. In nude mice bearing human xenograft breast tumors, nab-paclitaxel treated 
mice showed more complete regressions, longer time to recurrence, longer doubling time and prolonged 
survival compared to paclitaxel [12]. Moreover, pharmacokinetic modeling has shown that nab-
paclitaxel has lower risk for neutropenia when compared to equivalent dosing of paclitaxel due to 
shorter time of free paclitaxel concentration in serum [13, 14]. In a Phase III clinical trial in patients with 
metastatic breast cancer, nab-paclitaxel demonstrated higher response rates, better safety and side-effect 
profile compared to conventional paclitaxel, and improved survival in patients receiving it as second line 
therapy [15]. 
 
In pancreatic cancer, Von Hoff et al. published pre-clinical in vivo data showing that the aggregate 
tumor regression response in individual xenografts were 22/90 (24%), 34/95 (36%), and 53/96 (55%) for 
gemcitabine, nab-paclitaxel, and gemcitabine plus nab-paclitaxel, respectively [16]. The combination of 
nab-paclitaxel with gemcitabine was studied in a Phase I/II trial in patients with metastatic pancreatic 
cancer and showed promising clinical activity with improvement in median OS to 12.2 months [16] 
from 5.65 months with single agent gemcitabine [17]. The maximum-tolerated dose (MTD) for the 
combination was defined as gemcitabine 1000 mg/m2 IV and nab-paclitaxel 125 mg/m2 IV on days 1, 8, 
15 every 28 days [16]. This led to the MPACT International Multi-Center Phase III Trial conducted in 
861 patients comparing nab-paclitaxel plus gemcitabine to gemcitabine monotherapy as first line 
treatment of metastatic pancreatic adenocarcinoma. Results significantly favored the nab-paclitaxel plus 
gemcitabine arm of the trial with a median OS of 8.5 months (95% CI=7.89, 9.53) versus 6.7 months 
(95% CI=6.01, 7.23) in the gemcitabine arm. The HR of nab-paclitaxel plus gemcitabine/gemcitabine 
(HRA+G/G) was 0.72 (95% CI=0.617, 0.835) indicating a 28% overall reduction in the risk of death for 
patients receiving the combination of nab-paclitaxel and gemcitabine, p<0.0001, stratified log rank test 
[18]. The updated results from this trial were presented at the 2014 Gastrointestinal Cancers 
Symposium. The gemcitabine/nab-paclitaxel combination resulted in a statistically significant 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 10 of 45 
improvement in OS (8.7 versus 6.6 months; HR, 0.72; p<0.0001) compared to gemcitabine alone in 
patients with advanced pancreatic cancer [9]. Nab-paclitaxel has also shown anti-tumor activity in other 
advanced cancer types, including breast [15], lung [20], and melanoma [21] and has received FDA 
approval for use in breast, non-small cell lung and pancreatic cancers. 
 
Rationale for the Current Study and Dose Selection 
Given the high toxicity associated with current standard platinum-taxane combination regimen (like 
DCF) and poor tolerability, alternative regimens of taxane-platinum combinations are urgently needed. 
Hence our rationale to explore our combination of FOLFOX and nab-paclitaxel (FOLFOX-A) in 
advanced gastric /GEJ adenocarcinoma. We hypothesize that this combination (FOLFOX-A) will have a 
higher efficacy, a better tolerability, and enhanced patient reported outcomes. Hence, our proposed 
phase II single arm trial of FOLFOX + nab-paclitaxel in chemotherapy –naïve unresectable, advanced 
gastric /GEJ adenocarcinoma.  
 
Safran et al (ASCO 2014) reported the results of a phase I study of FOLFOX + Nab-paclitaxel in 
advanced pancreatic cancer that has established the MTD of the combination. The MTD for Nab-
paclitaxel was 150 mg /m2 IV Q 2 weeks when combined with FOLFOX regimen. In this phase I study, 
89% who received >10 cycles of the combination developed grade 2 neuropathy, 22% developed grade 
3 neuropathy. The study recommended oxaliplatin dose reduction to 65 mg/m2 if patients developed 
grade 2 neuropathy. Hence our rationale for this dosage of nab-paclitaxel when combined with 
FOLFOX as proposed in our study. 
 
2. 
STUDY OBJECTIVES AND ENDPOINTS 
 
Objectives 
 Primary Objective 
 To estimate the overall objective response rate (CR+PR) of FOLFOX combined with nab-paclitaxel 
(FOLFOX-A) in patients with advanced gastric, gastroesophageal junction adenocarcinoma.  
 Secondary Objectives 
 To evaluate clinical efficacy by assessment of median OS, PFS, TTP as well as best ORR and 
disease control rate (DCR) 
 Describe the safety and toxicity profile of the combination of nab-paclitaxel and FOLFOX in this 
population 
 
Endpoints  
 Primary Endpoint 
 Objective response rate will be calculated by combining the number of subjects who achieve 
complete response and partial response per RECIST 1.1 criteria 
 Secondary Endpoints 
 Assessment of median OS, PFS, TTP as well as best ORR and disease control rate (DCR) 
 Grade 3 and 4 toxicities as defined by the NCI Common Terminology Criteria for Adverse Events 
(NCI CTCAE) v4. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 11 of 45 
 
3. 
ELIGIBILITY CRITERIA 
Each of the criteria in the checklist that follows must be met in order for a patient to be considered 
eligible for this study. The target population for this study is patients with advanced gastric/GEJ 
adenocarcinoma.  This will be a multicenter trial conducted at participating sites within the Big Ten 
Cancer Research Consortium (Big Ten CRC). Northwestern University will serve as the lead site.  
 
Inclusion Criteria 
Subject must meet all of the following applicable inclusion criteria to participate in this study: 
 
2. Written informed consent and HIPAA authorization for release of personal health information. 
NOTE:  HIPAA authorization may be included in the informed consent or obtained separately. 
3. Age ≥ 18 years at the time of consent. 
4. ECOG Performance Status of 0-1 within 28 days prior to registration. 
5. Histologically-confirmed advanced or metastatic unresectable gastric carcinoma, or 
adenocarcinoma of the gastroesophageal junction. 
6. Prior neoadjuvant or adjuvant chemotherapy, hormonal therapy, immunotherapy, radiation or 
chemoradiotherapy must have been completed at least 6 months prior to documented recurrence 
or metastatic disease. NOTE: patients must not have received previous systemic treatment for 
metastatic disease. 
7. Evaluable disease according to RECIST v1.1 for solid tumors, within 28 days prior to 
registration.  
8. Demonstrate adequate organ function as described below; all screening labs to be obtained 
within 28 days prior to registration.  
a. Bilirubin < 1.5 mg/dL 
b. Patients must have adequate liver function: AST and ALT < 2.5  upper limit of normal, 
alkaline phosphatase < 2.5  upper limit of normal, unless bone or liver metastasis is present 
(≤5  upper limit of normal). 
c. Patients must have adequate bone marrow function: Platelets >100,000 cells/mm3 (transfusion 
independent, defined as not receiving platelet transfusions within 7 days prior to laboratory 
sample), Hemoglobin > 9.0g/dL and ANC > 1,500 cells/mm3. 
d. Patients must have adequate renal function: creatinine <1.5 mg/dL or creatinine clearance 
≥60mL/min is recommended; however, institutional norms are acceptable.  
9. Females of child-bearing potential (defined as a sexually mature woman who (1) has not 
undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the 
surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 
consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) 
must: 
a. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a 
monthly basis), or agree to use and be able to comply with effective contraception without 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 12 of 45 
interruption 28 days prior to starting investigational product (IP), and while on study 
medication (including dose interruptions) and for 30 days following the last dose of IP; and 
b. Have a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing 
pregnancy testing prior to each treatment and after the end of study therapy.  This applies even 
if the subject practices true abstinence* from heterosexual contact. 
c. Male subjects must practice true abstinence* or agree to use a condom during sexual contact 
with a pregnant female or a female of childbearing potential while participating in the study, 
during dose interruptions and for 6 months following IP discontinuation, even if he has 
undergone a successful vasectomy. 
*NOTE: True abstinence is acceptable when this is in line with the preferred and usual 
lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable methods of contraception]. 
 
Exclusion Criteria 
Subjects meeting any of the criteria below may not participate in the study: 
 
1. Her-2 positive gastric tumor. 
2. Treatment with any investigational products within 28 days prior to study registration. 
3. Preexisting peripheral neuropathy is not allowed from any cause. 
4. Known history of Human Immunodeficiency Virus (HIV) or Hepatitis C (baseline testing is not 
required). 
5. Patients with active sepsis or pneumonitis 
6. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 
Subjects with previously treated brain metastases may participate provided they are stable 
(without evidence of progression by imaging for at least four weeks prior to trial registration and 
any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain 
metastases, and are not using steroids for at least 7 days prior to trial registration. 
7. Known hypersensitivity to fluorouracil (5-FU), oxaliplatin, or other platinum agents. 
8. Known hypersensitivity to nab-paclitaxel or any of its excipients. 
9. History of slowly progressive dyspnea and unproductive cough, or pulmonary conditions such as 
sarcoidosis, silicosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis or multiple 
allergies. See section 6.5.1. 
10. Has known dihydropyrimidine dehydrogenase deficiency (DPD) deficiency (testing not required) 
11. Ongoing or active infection requiring systemic treatment (must be afebrile for ≥ 48 hours prior to 
study registration) 
12. Uncontrolled intercurrent illness including, but not limited to any of the following:  
 Symptomatic congestive heart failure 
 Unstable angina pectoris 
 Cardiac arrhythmia 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 13 of 45 
13. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother 
is being treated on study). 
14. Known additional malignancy within the past 3 years. Exceptions include treated localized basal 
cell or squamous cell carcinoma of the skin, in situ cervical or vulvar carcinoma that has 
undergone potentially curative therapy, superficial bladder tumors (Ta, Tis & T1), ductal 
carcinoma in situ (DCIS) of the breast and low grade prostate cancer (Gleason sore 6). Any 
cancer curatively treated > 3 years prior to registration with no clinical evidence of recurrence is 
permitted. 
15. Psychiatric illness/social situations that would limit compliance with study requirements. 
16. Any other illness or condition that the treating investigator feels would interfere with study 
compliance or would compromise the patient’s safety or study endpoints 
 
4. 
SUBJECT REGISTRATION 
All subjects must be registered through Big Ten CRC Administrative Headquarters’ electronic data 
capture (EDC) system, OnCore. A subject is considered registered when an ‘On Study’ date is entered 
into the EDC system. 
 
Subjects must be registered prior to starting protocol therapy. Subjects must begin therapy within 5 
business days of registration.  
 
5. 
TREATMENT PLAN 
This is an open label, single-arm phase II, multi-institutional trial to evaluate the efficacy and safety of 
the combination of nab-paclitaxel and FOLFOX (FOLFOX-A) as first line therapy for patients 
diagnosed with histologically-confirmed advanced gastric/GEJ adenocarcinoma.   
 
All patients will receive FOLFOX-A on days 1 and 15 of each cycle (1 cycle = 28 days). Nab-paclitaxel 
will be given at a dose of 150 mg/m2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m2 and 
leucovorin IV 400 mg/m2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for 
a total dose of 2400mg/m2 over 46-48 hours.). Radiographic assessment will be performed at baseline 
and every other cycle (starting with Cycle 3) to evaluate response to treatment by RECIST Version 1.1 
guidelines.  Patients may continue to receive treatment until disease progression or unacceptable 
toxicity.  The primary endpoint will be objective response rate (partial or complete response). A 
maximum of 39 patients will be enrolled. 
 
Pre-medication and Hydration 
Patients may receive premedication with diphenhydramine (25-50 mg IV) 30 minutes prior to nab-
paclitaxel or per institutional standards.   
 
Dose Calculations 
Body Surface Area (BSA) 
BSA calculations will be used for dosing of all drugs.  BSA should be calculated on Cycle 1 Day 1 
based on the subject’s current height and actual body weight using the DuBois formula. BSA will be 
recalculated per the site’s standard of care, or if Day 1 body weight changes by more than 10%.  Actual 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 14 of 45 
heights and weights should be used to calculate surface areas (no downward adjustment to "ideal" 
weight). This principle applies to individuals whose calculated surface area is 2.2 m2 or less. In those 
rare cases where a patient's surface area is greater than 2.2 m2, the actual surface area or 2.2 may be 
used. Dosing BSA may be capped if the treating physician believes it is in the best interest of an obese 
patient. 
 
Treatment Administration 
Patients may receive premedication with dexamethasone 20 mg within 12 hours prior to the nab-
paclitaxel. Diphenhydramine (25-50 mg IV) may be given 30 minutes prior to nab-paclitaxel or per 
institutional standards.  Nab-paclitaxel will be administered first followed by FOLFOX over a period of 
46-48 hours.  
 
Agent 
Full Dose Administration1 
Days of 
Administration2 
Nab-Paclitaxel3 
150 mg/m2 IV over 30-40 mins 
D1, D15 
Oxaliplatin 
85 mg/m2 IV over 2 hours (±15 min) 
D1, D15 
Leucovorin 
400 mg/m2 IV over 2 hours (±15 min).  
This may be given either concurrently with 
oxaliplatin (e.g. y-site or separate line) or 
after oxaliplatin has been infused, 
according to site standard procedures.
D1, D15 
5-FU 
2400 mg/m2 IV continuously over 46-48 
hours. 
Administer after oxaliplatin and leucovorin.
D1-2, D15-16 
1 Recalculate BSA per site standard of care or when Day 1 actual body weight 
changes by ≥ 10%. 
2 A window of +/- 3 days may be applied to all study visits to accommodate 
observed holidays, inclement weather, scheduling conflicts etc.  Date and time of 
each drug administration should be clearly documented in subject’s chart and 
electronic case report forms (eCRFs). 
3 Nab-Paclitaxel will be administered first, immediately followed by FOLFOX 
 
Patients will be monitored by infusion center nursing staff every 15 minutes during infusions or per 
institutional standards, and treatment will be interrupted for any evidence of an infusion reaction. If 
hypersensitivity symptoms develop, the infusion will be stopped. Patients will be treated with additional 
H1 antagonist, as well as an H2 antagonist (such as famotidine 20 mg or ranitidine 50 mg IV) at the 
discretion of the treating investigator. If hypersensitivity symptoms are mild (grade 1 or 2) and resolve 
over 30-60 minutes of observation with administration of additional H1 and H2 blockers, the study drug 
infusion may resume with caution at a reduced rate (over approximately 60 minutes), at the discretion of 
the treating investigator. Additional supportive care measures should be available at each study site 
infusion center in case of severe hypersensitivity reaction. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 15 of 45 
 
Concomitant Medications 
 Allowed Concomitant Medications 
All treatments the site investigator considers necessary for a subject’s welfare may be administered at 
the discretion of the site investigator in keeping with the community standards of medical care. All 
concomitant medication will be recorded on the case report form (CRF) including all prescription, over-
the-counter (OTC), herbal supplements, and IV medications and fluids.  If changes occur during the trial 
period, documentation of drug dosage, frequency, route, and date should also be included on the CRF. 
 
All concomitant medications received within 28 days before the first dose of trial treatment and 30 days 
after the last dose of trial treatment should be recorded. Concomitant medications administered 30 days 
after the last dose of trial treatment should be recorded if associated with SAEs. 
 Prohibited Concomitant Medications 
Subjects are prohibited from receiving the following therapies during the Screening and Treatment 
Phase of this trial. The Exclusion Criteria describes other medications that are prohibited in this trial. 
 
 Anti-cancer systemic chemotherapy or biological therapy  
 Chemotherapy not specified in this protocol 
 Investigational agents other than nab-paclitaxel 
 Radiation therapy  
 Note: Radiation therapy to a symptomatic solitary lesion or to the brain may be allowed after 
consultation with sponsor-investigator by contacting the Big Ten CRC project manager.  
 
Subjects who, in the assessment by the site investigator, require the use of any of the aforementioned 
treatments for clinical management should be removed from the trial treatment. Subjects may 
receive other medications that the site investigator deems to be medically necessary off trial 
treatment.  
 
There are no prohibited therapies during the Post-Treatment Follow-up Phase. 
 
Supportive Care 
Standard supportive care should be followed at each site per their guidelines. Patients should receive full 
supportive care, including transfusions of blood and blood products, antibiotics, antiemetics, etc., when 
appropriate. The use of epoetin products is not allowed. 
 
Supportive care measures may include but are not limited to the items outlined below: 
 
Nausea/vomiting:  
Nausea and vomiting should be treated aggressively, and consideration should be given in subsequent 
cycles to the administration of prophylactic antiemetic therapy according to standard institutional 
practice. Subjects should be strongly encouraged to maintain liberal oral fluid intake. 
 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 16 of 45 
Antimicrobials:  
Subjects with a documented infectious complication should receive oral or IV antibiotics or other anti-
infective agents as considered appropriate by the site investigator for a given infectious condition, 
according to standard institutional practice. 
 
Diarrhea/Colitis:  
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as 
peritoneal signs and ileus).   
 All subjects who experience diarrhea/colitis should be advised to drink liberal quantities of clear 
fluids.  If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted 
via IV infusion.  For Grade 2 or higher diarrhea, consider GI consultation and endoscopy to 
confirm or rule out colitis. 
 For Grade 2 diarrhea/colitis that persists greater than 3 days, administer oral corticosteroids.  
 For Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with intravenous steroids followed 
by high dose oral steroids.   
 When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks. 
 
6. 
TOXICITIES AND DOSE DELAYS/DOSE MODIFICATIONS 
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v4 will be used to grade adverse 
events.  
 
Subjects enrolled in this study will be evaluated clinically and with standard laboratory tests before and 
at regular intervals during their participation in this study as specified in Study Calendar & Evaluations. 
 
Subjects will be evaluated for adverse events (all grades), serious adverse events, and adverse events 
requiring study drug interruption or discontinuation as specified in Study Calendar & Evaluations.   
 
Dose Delays/Dose Modifications 
A new cycle of FOLFOX-nab-paclitaxel may not be administered to the participant until the following 
criteria are met: 
 the ANC has recovered according to Table 3; 
 the platelet count has recovered according to Table 3; 
 stomatitis or diarrhea have recovered to grade 1 or less; 
 fatigue has recovered to grade 2 or less.  
 All other study drug-related, clinically significant, non-hematological toxicity must have 
resolved to grade 1 or baseline. This does not include alopecia. 
 
If the patient does not meet these criteria, delay Day 1 until recovery to above guidelines. Delay the 
cycle until these requirements are met.  Patients who require a treatment delay of more than 6 weeks 
from the scheduled treatment day due to toxicity will be removed from protocol treatment. 
 
A list of the adverse events and potential risks associated with the agents administered in this study 
appear below and will determine whether dose delays and modifications will be made or whether the 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 17 of 45 
event requires expedited reporting in addition to routine reporting.  
 
Dose Levels for Dose Reductions 
The tables below indicate potential dose levels for each of the agents for which dose modifications will 
be allowed. It is recommended that treating investigators follow standard institutional practice 
guidelines for dose modification within the FOLFOX chemotherapy regimen. Dose adjustments of each 
agent may be made independently based on the specific types of toxicities observed. There will be no 
dose reduction of leucovorin. 
 
The following adjustments in the table below should be made to the appropriate drug (depending on the 
attribution of toxicity) based on the dose reduction guidelines. In addition, please note: 
 If more than one toxicity requiring dose reduction occurs, use lowest dose level required. 
 If multiple toxicities are seen, the dose administered in subsequent cycle should be based on the 
most severe toxicity experienced in the current cycle. 
 Patients not experiencing resolution of their neutropenia within 28 days (ANC ≥ 1.0 x 103 
cells/L), despite uninterrupted Granulocyte-Colony Stimulating Factor (G-CSF) treatment, will 
be discontinued from all study treatment. 
Table 2: FOLFOX-A Dose Modification Schedule 
 
Nab-paclitaxel 
Oxaliplatin 
Leucovorin 
5-FU 
Starting Dose 
level 
150 mg/m2 
85mg/m2 
400 mg/m2 
2400mg/m2 
Dose level -1 
120 mg/m2 
65 mg/m2 
400 mg/m2 
1920 mg/m2 
Dose level -2 
95 mg/m2 
50 mg/m2 
400 mg/m2 
1600 mg/m2 
 Each drug can be dose reduced a total of 2 times. All dose reductions are permanent. 
 
Hematologic Toxicities 
The following table describes the recommended dose modifications at the start of each course of 
therapy, based on the pretreatment labs for that cycle. 
 
Table 3: FOLFOX Dose Modification Guidelines 
Toxicity and Grade 
Action to be Taken 
Neutropenia (ANC) 
Grade 1: <LLN – 1.5 × 109/L 
Grade 2: 1.5 – 1.0 × 109/L 
Maintain dose level 
Grade 3: <1.0 - 0.5 × 109/L 
Hold FOLFOX-A. When ANC has recovered to ≤ grade 2, 
resume treatment and decrease oxaliplatin by one dose level.
Grade 4: <0.5 × 109/L 
Hold FOLFOX-A and check CBC weekly. When ANC has 
recovered to ≤ grade 2, resume treatment and decrease both 5-
FU and oxaliplatin by one dose level. 
If ANC < 1.0 × 109/L after 4 weeks, discontinue therapy.
Thrombocytopenia (PLT) 
Grade 1: <LLN – 75.0 × 109/L 
Maintain dose level.

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 18 of 45 
Toxicity and Grade 
Action to be Taken 
Grade 2: <75.0 – 50.0 × 109/L 
Grade 3: <50.0 – 25.0 × 109/L 
Hold FOLFOX-A. When PLT has recovered to ≤ grade 1, 
resume treatment and decrease oxaliplatin by one dose level.
Grade 4: <25.0 × 109/L 
Hold FOLFOX-A and check CBC weekly. When PLT has 
recovered to ≤ grade 1, resume treatment and decrease both 5-
FU and oxaliplatin by one dose level. 
If PLT < 75 × 109/L after 4 weeks, discontinue therapy.
Febrile Neutropenia 
Grade 3 or greater: 
ANC <1.0 × 109/L and fever 
38.5°C (101°F) 
Hold FOLFOX-A and check CBC weekly. When ANC has 
recovered to >1.0 × 109/L, and any infection is under control, 
resume treatment and decrease both 5-FU and oxaliplatin by 
one dose level. 
If ANC < 1.0 × 109/L after 4 weeks, and/or fever or infection 
has not resolved after 4 weeks, discontinue therapy. 
 
Neuropathy 
The goal of the following dose modifications are to prevent patients from developing grade 3/4 
neuropathy during or after completion of FOLFOX-A. Fluorouracil and leucovorin will not be reduced 
for neuropathy. 
 For patients experiencing grade 2 neuropathy: 
 Hold Oxaliplatin  
 To reinstitute oxaliplatin in patients with a first episode of grade 2 neuropathy, neuropathy must 
have improved to Grade < 1, however, nab-paclitaxel, 5-FU and leucovorin may be 
administered. Oxaliplatin should be permanently reduced to dose level - 1 (65mg/m2). Nab-
paclitaxel, 5-FU and leucovorin will not be reduced for grade 2 neuropathy.  
 To reinstitute oxaliplatin in patients with a second episode of grade 2 neuropathy, neuropathy 
must have improved to Grade < 1, however, nab-paclitaxel, 5-FU and leucovorin may be 
administered. Oxaliplatin should be permanently reduced dose level - 2 (50mg/m2). Nab-
paclitaxel, 5-FU and leucovorin will not be reduced for grade 2 neuropathy.  
 Oxaliplatin should be permanently discontinued for patients developing a third episode of grade 
2 neuropathy. However, nab-paclitaxel, 5-FU and leucovorin may be continued. 
 At the investigator’s discretion, FOLFOX-A may be held for up to six weeks secondary to 
patient’s experiencing grade 2 neuropathy. The reason for hold (grade 2 neuropathy) must be 
documented in the eCRF. 
 For patients experiencing grade 3 neuropathy: 
 Hold FOLFOX-A until neuropathy improves to < grade 1.  
 When treatment is resumed after the first episode, oxaliplatin and nab-paclitaxel should be 
permanently decreased to 65mg/m2 and 120mg/m2 respectively (dose level -1). 5-FU and 
Leucovorin will not be reduced for grade 3 neuropathy. 
 When treatment is resumed after the second episode, oxaliplatin and nab-paclitaxel should be 
permanently decreased to 50mg/m2 and 95mg/m2 respectively (dose level -2).  
 Patients developing a third episode of grade 3 neuropathy should be removed from study 
treatment. The reason for patient discontinuation must be documented as secondary to grade 3 
neuropathy. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 19 of 45 
 At the investigator’s discretion, FOLFOX-A may be held for up to six weeks secondary to 
patient’s experiencing grade 3 neuropathy. The reason for hold (grade 3 neuropathy) must be 
documented in the eCRF. 
 Grade 4 neuropathy: 
 For patients experiencing grade 4 neuropathy, patients must come off study treatment. 
 
Interstitial Pneumonitis  
Interstitial pneumonitis has been observed in < 1% during nab-paclitaxel monotherapy and in < 1% 
during combination treatment with nab-paclitaxel and carboplatin. However, the risk has been higher for 
the combination of nab-paclitaxel with gemcitabine. Pneumonitis has been reported at a rate of 4% with 
the use of nab-paclitaxel in combination with gemcitabine. Monitor patients closely for signs and 
symptoms of pneumonitis. After ruling out infectious etiology and upon making a diagnosis of 
pneumonitis, permanently discontinue treatment with nab-paclitaxel and promptly initiate appropriate 
treatment and supportive measures. 
 Prevention, Surveillance and Management of Interstitial Pneumonitis: 
 Before starting treatment with nab-paclitaxel candidates should be evaluated for familial, 
environmental or occupational exposure to opportunistic pathogens: do not enroll patients with a 
history of slowly progressive dyspnea and unproductive cough, or pulmonary conditions such as 
sarcoidosis, silicosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis or multiple 
allergies. 
 During treatment with nab-paclitaxel episodes of transient or repeated dyspnea with 
unproductive persistent cough or fever should be paid attention to. Radiographic evaluation with 
chest X-rays and computed tomography (CT) scans (normal or high resolution) may be indicated 
to look for infiltrates ground-glass opacities or honeycombing patterns. Pulse oximetry and 
pulmonary function tests can show respiratory and ventilation compromise. 
 Infections should be ruled out with routine microbiological and/or immunologic methods. 
Transbronchial lung biopsy is not recommended, given its limited value and risk of 
pneumothorax and hemorrhage, and should be reserved for cases with unclear etiology. 
 Upon a diagnosis of interstitial pneumonitis nab-paclitaxel should be permanently discontinued. 
After ruling out an infectious etiology, intravenous high-dose corticosteroid therapy should be 
instituted without delay, with appropriate premedication and secondary pathogen coverage. 
Patients with an added immunological component may also require immune modulation with 
azathioprine or cyclophosphamide. Appropriate ventilation and oxygen support should be used 
when required. 
 
Sepsis:  
Sepsis occurred in 5% in patients with or without neutropenia receiving nab-paclitaxel/gemcitabine. 
Biliary obstruction or presence of biliary stent, were risk factors for severe or fatal sepsis. If a patient 
becomes febrile (regardless of neutrophil count), initiate treatment with broad spectrum antibiotics. For 
febrile neutropenia, withhold nab-paclitaxel until fever resolves and ANC ≥ 1500, then resume 
treatment and reduce all drugs by one dose level. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 20 of 45 
 
Protocol Therapy Discontinuation 
In addition to discontinuation from therapy related to toxicities, a subject will also be discontinued from 
protocol therapy and followed up per protocol under the following circumstances: 
 
Evidence of disease progression  
 
The treating physician thinks a change of therapy would be in the best interest of the subject 
 
The subject requests to discontinue protocol therapy, whether due to unacceptable toxicity or for 
other reasons 
o In case a subject decides to prematurely discontinue protocol therapy (“refuses treatment”), 
the subject should be asked if she or he may still be contacted for further scheduled study 
assessments. The outcome of that discussion should be documented in both the medical 
records and in the eCRF. 
 
A female subject becomes pregnant  
 
If protocol therapy is interrupted for ≥ 6 weeks.  
 
Subjects will be removed from protocol therapy and the site investigator notified when any of the 
criteria listed above apply.  The reason for discontinuation of protocol therapy will be documented on 
the electronic case report form (eCRF).   
 
Study Withdrawal 
If a subject decides to withdraw from the study (and not just from protocol therapy) all efforts should be 
made to complete and report study assessments as thoroughly as possible. The treating investigator 
should contact the subject or a responsible relative by telephone or through a personal visit to establish 
as completely as possible the reason for the study withdrawal. A complete final evaluation at the time of 
the subject’s study withdrawal should be made with an explanation of why the subject is withdrawing 
from the study. If the reason for removal of a subject from the study is an adverse event, it will be 
recorded on the eCRF. 

Big Ten Cancer Research Consortium 
 
 
  
Clinical Study Protocol 
 
 
 
 
     
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 21 of 45 
7. 
STUDY CALENDAR & EVALUATIONS 
Cycle = 28 days
Screening 
Cycle 1 and 
following 
D1 every 
odd cycle2,3 
Safety 
F/U
Long-term 
F/U5
-28 days1 
Day 
12
Day 
152 
30 days2,4
Q 3mos 
(±14)
REQUIRED ASSESSMENTS 
 
Informed Consent 
X
 
Diagnosis and Staging6 
X
 
Medical history6 
X
 
Physical exam 
X
X
X 
X
Vital signs, ECOG Performance status8
X
X
X 
X
AEs & concomitant medications
X
X
X 
X
X5
LABORATORY ASSESSMENTS 
 
Complete Blood Cell Count with diff (CBC)
X
X
X 
X
Comprehensive Metabolic Profile (CMP)9
X
X
X 
X
Mg, Phos, Uric Acid, LDH
X
X
X 
PT/INR and aPTT7 
X
 
CA19-9 
X
 
X
X
Pregnancy test (serum or urine) WOCBP10
-7d10
X
 
DISEASE ASSESSMENTS11 
 
CT of chest 
X
 
X
X11
CT or MRI of abdomen and pelvis
X
 
X
X11
TREATMENT EXPOSURE 
 
Nab-paclitaxel  
X
X 
FOLFOX7 
X
X 
CORRELATIVE STUDIES (SPECIMEN COLLECTION)
 
Tumor block or unstained slides12 (if available)
C1
 
Blood sample13 
C1
 
BANKING SAMPLES (SPECIMEN COLLECTION) 
 
Whole Blood 
C1
 
Unstained Slides (if available)
C1
 
Serum and Plasma 
C1
 
X
FOLLOW-UP 
 
Survival status; Subsequent therapy 
 
X
 
 

Big Ten Cancer Research Consortium 
 
 
  
Clinical Study Protocol 
 
 
 
 
     
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 22 of 45 
Footnotes  
Screening evaluations are to be conducted within 28 days prior to study registration. Scans must be done <4 weeks prior to study registration. All 
laboratory and other assessments must be performed prior to administration of any study medication, however a window of +/- 7 days will be 
allowed to change patient schedule without PI or IRB approval. 
1If screening (baseline) labs were performed within 7 days of D1 of treatment, these do not need to be repeated.   
2A window of 3 days will be applied to all treatment study visits; for safety follow-up visit and every other cycle tumor imaging, imaging may take 
place within 7 days prior to the study visit. 
3Tumor imaging to continue every odd numbered cycle until progression, starting with cycle 3. 
4The safety follow-up visit should occur when subjects permanently stop study treatment for whatever reasons (toxicity, progression, or at 
discretion of site investigator) and should be performed 30 days (±7 days) after the last dose of treatment. Subjects who have an ongoing ≥grade 2 
or serious AE (SAE) at this visit will continue to be followed until the event is resolved or deemed irreversible by the site investigator.  
5Long-term follow up will occur every 3 months from the last administration of protocol-directed therapy or until death, and may be conducted via 
telephone. Subjects who have ongoing Grade 4 AE or SAE at the time of discontinuation from treatment, and those who come off treatment 
prematurely for safety reasons will continue to be followed until the event is resolved or deemed irreversible by the site investigator.  
6Diagnosis and staging to include pathology report and Tumor Node Metastasis (TNM) staging. Medical history will include smoking history and 
trial awareness question (see Documents/Info tab of OnCore). Medical history will also include tumor mutational testing results, if previously 
performed (PD-L1; microsatellite instability [MSI]; mismatch repair [MMR]). 
7 Concomitant administration of 5-FU with warfarin has been reported to result in increased INR/prolonged prothrombin time. Participants 
receiving both drugs should be followed with weekly INRs. 
8Vital signs to include blood pressure, weight, and height (screening only) and ECOG performance status 
9CMP to include Na, K, Cl, creatinine, BUN; liver function tests (LFTs) to include AST, ALT, total bilirubin, alkaline phosphatase  
10Women of childbearing potential (WOCBP) must have serum β-HCG testing within 7 days prior to Cycle 1 Day 1 of FOLFOX-A and prior to 
Day 1 of every Cycle thereafter (serum or urine).  If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be 
required.  
11Tumor response assessment will be performed every odd numbered cycle starting with cycle 3; tumor imaging to be done at treatment 
discontinuation at discretion of investigator. Additional imaging should be obtained at investigator’s discretion if there is suspicion of other sites 
metastatic involvement. If imaging is positive at baseline, it should be included with subsequent tumor response assessments as noted above. If a 
patient is removed from treatment for reason(s) other than progression, follow with regular tumor assessments per standard of care until 
progression or start of new treatment. 
12Fixed paraffin-embedded blocks or unstained slides will be requested from tumor specimen in all subjects (optional).  See Correlative Laboratory 
Manual (CLM) for additional details. 
13Baseline pretreatment blood sample will be collected to support biomarker research.  See CLM for additional details. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 23 of 45 
 
Safety Follow-up Visit Evaluations 
Subjects discontinued from the treatment phase of the study for any reason will be evaluated 30 days (± 
7) after the last dose of study drug.  Medical history, physical exam, performance status, review of 
medications, and assessment of adverse events will be documented.  
 
Long Term Follow-up Evaluations 
After treatment discontinuation, follow-up for survival and initiation of any other anti-cancer therapies 
will be documented every 3 months for up to 2 years from treatment discontinuation or until death, 
whichever comes first. The study will end 2 years after the final patient discontinues treatment or after 
all patients are deceased, whichever comes first. If a patient continues to do well on the study drug 
combination, follow-up will cease 3 years after first date of treatment but patient may continue to 
receive the combination treatment from the local investigator apart from this clinical trial.  
 
If a patient is removed from treatment for reason(s) other than progression, follow with regular tumor 
assessments per standard of care until progression or start of new treatment. 
 
8. 
BIOSPECIMEN STUDIES 
 
Correlative studies 
Baseline tissue and blood will be collected for future biomarker studies and next generation sequence 
analysis.  
 
Samples for future studies 
Subject consent will be obtained for additional samples collected for future Big Ten Cancer Research 
Consortium studies. Hoosier Cancer Research Network, as Administrative Headquarters for the Big Ten 
CRC, will manage the banked samples. Samples will be banked indefinitely in the Hoosier Cancer 
Research Network Biorepository.  
 
This includes: 
 Whole blood: Whole blood will be collected prior to treatment on Cycle 1 Day 1.  
 Pre- and Post-treatment plasma: Whole blood for plasma will be collected prior to treatment on Cycle 
1 Day 1 and at the 30-day Safety Follow-up visit.  
 Pre- and Post-treatment serum: Whole blood for serum will be collected prior to treatment on Cycle 1 
Day 1 and at the 30-day Safety Follow-up visit. 
 Unstained slides: Unstained slides will be obtained from the subject’s archived formalin fixed paraffin 
embedded tumor sample.  
 
Please refer to the Correlative Laboratory Manual (CLM) for all sample collection, processing, labeling, 
and shipping instructions. 
 
Confidentiality of Biospecimens 
Samples will be identified by a subject’s study number assigned at the time of registration to the trial. 
Any material issued to collaborating researchers will be anonymized and only identified by the subject’s 
study number. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 24 of 45 
9. 
CRITERIA FOR DISEASE EVALUATION 
 
Measurable Disease 
Measurable disease is defined as the presence of at least one measurable lesion. Measurable lesions are 
defined as those that can be accurately measured in at least one dimension (longest diameter to be 
recorded) as >20 mm by chest x-ray, as >10 mm with CT scan, or >10 mm with calipers by clinical 
exam.  All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters). 
 Malignant Lymph Nodes 
To be considered pathologically enlarged and measurable, a lymph node must be >15 mm in short axis 
when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm).  At 
baseline and in follow-up, only the short axis will be measured and followed. 
 
Non-measurable Lesions 
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or pathological 
lymph nodes with ≥ 10 to <15 mm short axis), are considered non-measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, 
inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as 
non-measurable. 
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, 
simple cysts. ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non-cystic lesions are 
present in the same subject, these are preferred for selection as target lesions. 
 
Target Lesions 
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of 
all involved organs, should be identified as target lesions and recorded and measured at baseline.  Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be representative 
of all involved organs, but in addition should be those that lend themselves to reproducible repeated 
measurements.  It may be the case that, on occasion, the largest lesion does not lend itself to 
reproducible measurement in which circumstance the next largest lesion which can be measured 
reproducibly should be selected.  A sum of the diameters (longest for non-nodal lesions, short axis for 
nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If 
lymph nodes are to be included in the sum, then only the short axis is added into the sum.  The baseline 
sum diameters will be used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease. 
 
Non-target Lesions 
All other lesions (or sites of disease) including any measurable lesions over and above the 5 target 
lesions should be identified as non-target lesions and should also be recorded at baseline.  Measurements 
of these lesions are not required, but the presence, absence, or in rare cases unequivocal progression of 
each should be noted throughout follow-up. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 25 of 45 
 
Evaluation of Target Lesions 
NOTE: In addition to the information below, also see section 4.3.2 in the international criteria proposed 
by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee, version 1.1 (Eur J Cancer 
45;2009:228-247) for special notes on the assessment of target lesions.  
 
Complete 
Response (CR) 
Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non-target) must have reduction in 
short axis to <10 mm.
Partial Response 
(PR) 
At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters 
Progressive 
Disease (PD) 
At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this 
includes the baseline sum if that is the smallest on study).  In 
addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm.  (Note:  the 
appearance of one or more new lesions is also considered 
progressions).
Stable Disease 
(SD) 
Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum 
diameters while on study
 
Evaluation of Non-Target Lesions 
Complete Response (CR) 
Disappearance of all non-target lesions and 
normalization of tumor marker level.  All lymph 
nodes must be non-pathological in size (<10 mm 
short axis) 
 
Note:  If tumor markers are initially above the upper 
normal limit, they must normalize for a subject to be 
considered in complete clinical response. 
Non-CR/ Non-PD 
Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal 
limits
Progressive Disease (PD) 
Appearance of one or more new lesions and/or 
unequivocal progression of existing non-target 
lesions.  Unequivocal progression should not 
normally trump target lesion status.  It must be 
representative of overall disease status change, not a 
single lesion increase.
 
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the site 
investigator should prevail in such circumstances, and the progression status should be confirmed at a 
later time by the sponsor investigator. 
 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 26 of 45 
 
Evaluation of Best Overall Response 
 
Target Lesions 
Non-Target Lesions 
New Lesions
Overall 
Response 
CR 
CR 
No 
CR 
CR 
Non-CR/ Non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD/ or not all 
evaluated
No 
PR 
SD 
Non-PD or not all evaluated 
No 
SD 
Not all evaluated 
Non-PD 
No 
Non-evaluable 
PD 
Any 
Yes or No 
PD 
Any 
PD* 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
*In exceptional circumstances, unequivocal progression in non-target lesions may be 
accepted as disease progression.
Subjects with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be classified as having “symptomatic 
deterioration”.  Every effort should be made to document the objective progression even after 
discontinuation of treatment. 
 
In some circumstances, it may be difficult to distinguish residual disease from normal tissue.  When the 
evaluation of complete response depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspirate/biopsy) to confirm the complete response status. 
 
10. 
DRUG INFORMATION 
 
Nab-Paclitaxel (Abraxane®) 
Please see the current package insert for complete product information. 
 Classification 
Antimicrotubular, Cytotoxic 
 Mode of Action 
Nab-paclitaxel is a microtubule inhibitor that promotes the assembly of microtubules from tubulin 
dimers and stabilizes microtubules by preventing depolymerization. This stability results in the 
inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital 
interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of 
microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. 
 Supplier/How Supplied 
Celgene will supply nab-paclitaxel at no charge to subjects participating in this clinical trial.  

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 27 of 45 
 
The investigator shall take responsibility for and shall take all steps to maintain appropriate records and 
ensure appropriate supply, storage, handling, distribution, and usage of the product in accordance with 
the protocol and any applicable laws and regulations. 
 Preparation  
Nab-paclitaxel is a cytotoxic drug and, as with other potentially toxic paclitaxel compounds, caution 
should be exercised in handling nab-paclitaxel. The use of gloves is recommended. If nab-paclitaxel 
(lyophilized cake or reconstituted suspension) contacts the skin, wash the skin immediately and 
thoroughly with soap and water. Following topical exposure to paclitaxel, events may include tingling, 
burning and redness. If nab-paclitaxel contacts mucous membranes, the membranes should be flushed 
thoroughly with water.  
 
Reconstitution of Nab-Paclitaxel  
o Aseptically, reconstitute each vial of nab-paclitaxel by injecting 20 ml of 0.9% Sodium Chloride 
Injection, USP or equivalent into each vial.  
o Slowly inject the 20 ml of 0.9% Sodium Chloride Injection, USP, over a minimum of 1 minute, 
using the sterile syringe directing the solution flow onto the inside wall of the vial.  
o DO NOT INJECT the 0.9% Sodium Chloride Injection, USP directly onto the lyophilized cake 
as this will result in foaming.  
o Once the injection is complete, allow the vial to sit for a minimum of 5 minutes to ensure 
proper wetting of the lyophilized cake/powder.  
o Gently swirl and/or invert the vial slowly for at least 2 minutes until complete dissolution of any 
cake/powder occurs. Avoid generation of foam.  
o Each ml of reconstituted product will contain 5 mg of nab-paclitaxel.  
 
1. The reconstituted suspension should be milky and homogeneous without visible particulates. If 
unsuspended powder is visible, the vial should be gently inverted again to ensure complete 
resuspension, prior to use.  
2. Inject the calculated dosing volume of reconstituted nab-paclitaxel into an empty sterile, IV bag.  
3. The use of in-line filters is not recommended.  
 
Refer to Abraxane® Package Insert for full prescribing information. 
 Storage and Stability 
Store the vials in original cartons at 20ºC to 25ºC (68ºF to 77ºF). Retain in the original package to 
protect from bright light. Unopened vials of nab-paclitaxel are stable until the date indicated on the 
package when stored between 20ºC to 25ºC (68ºF to 77ºF) [excursions permitted between 15ºC to 30ºC 
(59ºF to 86ºF)], in the original package. Neither freezing nor refrigeration adversely affects the stability 
of the product.  
 
Stability of Reconstituted Suspension in the Vial 
Reconstituted nab-paclitaxel in the vial should be used immediately, but may be refrigerated at 2ºC to 
8ºC (36ºF to 46ºF) for a maximum of 8 hours if necessary. If not used immediately, each vial of 
reconstituted suspension should be replaced in the original carton to protect it from bright light. Discard 
any unused portion.  

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 28 of 45 
 
Stability of Reconstituted Suspension in the Infusion Bag 
The suspension for infusion when prepared as recommended in an infusion bag should be used 
immediately but may be stored at ambient temperature (approximately 25ºC) and lighting conditions 
for up to 4 hours. Discard any unused portion. 
 Dispensing 
Nab-paclitaxel must be dispensed only from official study sites and to eligible subjects under the 
supervision of the site investigator. Nab-paclitaxel should be stored in a secure area according to local 
regulations.  It is the responsibility of the site investigator to ensure that study drug is only dispensed to 
subjects.   
 Adverse Events 
The most common adverse reactions (≥ 20%) with single-agent use of nab-paclitaxel in metastatic 
breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, 
myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and 
diarrhea. 
 
The most common adverse reactions (≥ 20%) of nab-paclitaxel in combination with carboplatin for 
non-small cell lung cancer are anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, 
nausea, and fatigue. The most common serious adverse reactions of nab-paclitaxel in combination with 
carboplatin for non-small cell lung cancer are anemia (4%) and pneumonia (3%). The most common 
adverse reactions resulting in permanent discontinuation of nab-paclitaxel are neutropenia (3%), 
thrombocytopenia (3%), and peripheral neuropathy (1%). The most common adverse reactions 
resulting in dose reduction of nab-paclitaxel are neutropenia (24%), thrombocytopenia (13%), and 
anemia (6%). The most common adverse reactions leading to withholding or delay in nab-paclitaxel 
dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%).  
 
In a randomized open-label trial of nab-paclitaxel in combination with gemcitabine for pancreatic 
adenocarcinoma, the most common (≥ 20%) selected (with a ≥ 5% higher incidence) adverse reactions 
of nab-paclitaxel are neutropenia, fatigue, peripheral neuropathy, nausea, alopecia, peripheral edema, 
diarrhea, pyrexia, vomiting, decreased appetite, rash, and dehydration. The most common serious 
adverse reactions of nab-paclitaxel (with a ≥ 1% higher incidence) are pyrexia (6%), dehydration (5%), 
pneumonia (4%) and vomiting (4%). The most common adverse reactions resulting in permanent 
discontinuation of nab-paclitaxel are peripheral neuropathy (8%), fatigue (4%) and thrombocytopenia 
(2%). The most common adverse reactions resulting in dose reduction of nab-paclitaxel are neutropenia 
(10%) and peripheral neuropathy (6%). The most common adverse reactions leading to withholding or 
delay in nab-paclitaxel dosing are neutropenia (16%), thrombocytopenia (12%), fatigue (8%), 
peripheral neuropathy (15%), anemia (5%) and diarrhea (5%). 
 
 
5-Fluorouracil (5-FU, Fluorouracil, Adrucil) 
Please see the current package insert for complete product information. 
 Supplier/How Supplied 
Commercial supplies of 5-FU will be used in this study and billed to third party payers or the subject. 
 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 29 of 45 
The investigator shall take responsibility for and shall take all steps to maintain appropriate records and 
ensure appropriate supply, storage, handling, distribution, and usage of the product in accordance with 
the protocol and any applicable laws and regulations. 
 Storage and Stability 
Intact vials should be stored at room temperature and protected from light. Slight yellow discolor does 
not usually indicate decomposition. Stability in ambulatory pumps varies according to the pump, 
manufacturer of drug, concentration, and diluent.  
 Compatibility 
Leucovorin enhances the cytotoxicity of 5-FU by forming a more stable tertiary complex with 
thymidylate synthase. Concomitant administration of 5-FU with warfarin has been reported to result in 
increased INR/prolonged prothrombin time. Participants receiving both drugs should be followed with 
weekly INRs. 
 Preparation  
Inspect for precipitate; if found, agitate or gently heat in water bath.  
 
46-48 hour infusion of 5-FU should be prepared for administration via ambulatory infusion pump 
according to the individual institution’s standards. These solutions may be prepared in D5W or 0.9% 
NaCl. 5-FU should not be mixed in the same solution with most parenteral anti-emetics. 
 Availability 
5-FU is commercially available as a 50 mg/mL solution for injection in 10 mL, 20 mL, 50 mL, and 100 
mL vials. 5-FU will not be provided by the study as it is considered standard of care.  
 Adverse Events 
 Nausea, diarrhea, vomiting (mild) 
 Stomatitis: 5-8 days after treatment initiation 
 Myelosuppression: granulocytopenia (9-14 days) 
 Thrombocytopenia (7-14 days) 
 Alopecia 
 Loss of nails 
 Hyperpigmentation 
 Photosensitivity 
 Maculopapular rash 
 Palmar–plantar erythrodysesthesias: (42-82% receiving continuous infusion) 
 CNS effects: cerebral ataxia (rare) 
 Cardiotoxicity: MI, angina 
 Asymptomatic S–T changes 68% 
 Ocular effects: excessive lacrimation and less commonly, tear duct stenosis 
 
 
Leucovorin (Leucovorin Calcium, Folinic Acid, Citrovorum Factor, N 5- 
Formyltetrahydrofolate, 5-Formyl-FH4) 
Please see the current package insert for complete product information. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 30 of 45 
 Supplier/How Supplied 
Commercial supplies of leucovorin will be used in this study and billed to third party payers or the 
subject. 
 
The investigator shall take responsibility for and shall take all steps to maintain appropriate records and 
ensure appropriate supply, storage, handling, distribution, and usage of the product in accordance with 
the protocol and any applicable laws and regulations. 
 Preparation  
Leucovorin may be reconstituted with BWI or with sterile water for injection. Solutions should be 
further diluted in D5W, 0.9% NaCl, or Ringers solution for infusion over two hours. 
 Storage and Stability 
Intact vials should be stored at room temperature and protected from light. Solutions reconstituted with 
BWI are stable for at least 7 days at room temperature. Solutions diluted for infusion are stable for 24 
hours at room temperature and 4 days under refrigeration. 
 Adverse Events 
The only adverse reactions associated with leucovorin are allergic reactions. These are extremely 
uncommon. 
 
 
Oxaliplatin (Eloxatin) 
Please see the current package insert for complete product information. 
 Supplier/How Supplied 
Commercial supplies of oxaliplatin will be used in this study and billed to third party payers or the 
subject. 
 
The investigator shall take responsibility for and shall take all steps to maintain appropriate records and 
ensure appropriate supply, storage, handling, distribution, and usage of the product in accordance with 
the protocol and any applicable laws and regulations. 
 Preparation  
The calculated dose of oxaliplatin should be diluted for infusion with 250 mL to 500 mL in D5W. 
Oxaliplatin should not be diluted with a sodium chloride solution. Needles, syringes, catheters, or IV 
administration sets containing aluminum should not be used with oxaliplatin. As with other platinum 
compounds, contact with aluminum may result in a black precipitate. 
 Storage and Stability 
Intact vials should be stored at room temperature. Solutions diluted in D5W are stable for 6 hours at 
room temperature or 24 hours under refrigeration. 
 Administration 
Oxaliplatin must be dispensed only from official study sites and to eligible subjects under the 
supervision of the site investigator. Oxaliplatin should be stored in a secure area according to local 
regulations. It is the responsibility of the site investigator to ensure that study drug is only dispensed to 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 31 of 45 
subjects. Oxaliplatin is injected into a vein [intravenous (I.V.) infusion] over 2 hours (±15 min). 
Oxaliplatin is incompatible in solution with alkaline medications or media (such as basic solutions of 5-
fluorouracil) and must not be mixed with these or administered simultaneously through the same 
infusion line. The infusion line should be flushed with 5% Dextrose Injection, USP prior to 
administration of any concomitant medication. 
 Adverse Events 
The most commonly observed oxaliplatin toxicities include neurotoxicity, GI toxicity, and 
myelosuppression.  
 
Three neurotoxicity syndromes have been seen: acute sensory neuropathy develops within hours to 2 
days after oxaliplatin administration. Symptoms include paresthesias, dysesthesias, and hypoesthesia of 
the hands, feet, and perioral region. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain and a 
sensation of chest pressure have also been noted. Acute sensory neuropathy symptoms may be 
exacerbated by exposure to cold temperature or cold objects. Symptoms are reversible, usually 
resolving within 14 days and commonly recurring with further dosing. This syndrome has been 
observed in about 56% of patients receiving oxaliplatin with 5-FU and leucovorin.  
 
Acute pharyngolaryngeal dysesthesia is reported to occur in 1-2% of patients. This syndrome is 
characterized by a subjective sensation of difficulty breathing or swallowing without laryngospasm or 
bronchospasm or objective evidence of hypoxia. Avoidance of cold drinks, food and air is suggested in 
order to minimize pharyngolaryngeal dysesthesia. Antianxiety agents (e.g., lorazepam) may be used to 
treat pharyngolaryngeal dysesthesias once oxygen saturation has been documented to be normal.  
 
Peripheral neuropathy persisting > 14 days is characterized by paresthesias, dysesthesias, and 
hypoesthesia. Abnormalities in proprioception may also be seen. Symptoms of persistent neuropathy 
may improve upon discontinuation of oxaliplatin.  
 
Gastrointestinal toxicities include nausea, vomiting (oxaliplatin is considered to be moderately 
emetogenic) and diarrhea.  
 
Neutropenia is reported in 73% of patients receiving oxaliplatin with 5-FU and leucovorin (44% grade 
3 or 4). Grade 3 or 4 thrombocytopenia is reported to occur in 4% of patients receiving the 
combination.  
 
Allergic reactions, similar to those seen with other platinum compounds, have also been observed in 
patients treated with oxaliplatin. Reactions range from rash to anaphylaxis.  
 
Rarely, oxaliplatin has been associated with pulmonary fibrosis, which may be fatal. Oxaliplatin should 
be discontinued in the presence of unexplained pulmonary symptoms (e.g. nonproductive cough, 
dysphagia) or pulmonary infiltrates until interstitial lung disease or pulmonary fibrosis have been ruled 
out. 
 
Recent reports of oxaliplatin extravasation suggest that tissue necrosis may result and that oxaliplatin 
should be considered a vesicant. No standard treatment exists for oxaliplatin extravasation although 
heat and sodium thiosulfate have both been suggested.  
 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 32 of 45 
Veno-occlusive disease (VOD) of the liver is a rare complication associated with oxaliplatin and 5-FU. 
Clinical manifestations of VOD include hepatomegaly, ascites, and jaundice. Histologically, VOD is 
characterized by diffuse damage in the centrilobular zone of the liver. Sequelae of VOD include 
hepatomegaly, splenomegaly, portal hypertension, and esophageal varices. A recent analysis of resected 
liver metastases in 153 patients indicated histological findings consistent with VOD in 6/27 patients 
who received 5-FU alone, 4/17 patients who received 5-FU and irinotecan, 20/27 patients who received 
5-FU and oxaliplatin, and 14/16 who received 5-FU, oxaliplatin and irinotecan. The remaining 66 
patients had not received chemotherapy prior to resection. There were no such findings in these 
patients.  
 
For more information on toxicities associated with oxaliplatin, please see the package insert. 
 
11. 
ADVERSE EVENTS 
The descriptions and grading scales found in the NCI CTCAE v4 will be utilized for AE assessment. A 
copy of the CTCAE v4 can be downloaded from the CTEP website at http://ctep.cancer.gov. All forms 
for AE/SAE recording and reporting can be found in OnCore (Documents and Information Tab). 
 
Definitions 
 Adverse Event (AE) 
An AE is any untoward medical occurrence whether or not considered related to the study drug that 
appears to change in intensity during the course of the study. The following are examples of AEs:  
 Unintended or unfavorable sign or symptom 
 A disease temporally associated with participation in the protocol 
 An intercurrent illness or injury that impairs the well-being of the subject 
 Abuse, withdrawal, sensitivity or toxicity to an investigational product 
 An overdose (defined as 10% over the protocol-specified dose), accidental or intentional, 
whether or not it is associated with an AE, should be recorded. Any sequela of an accidental or 
intentional overdose of an investigational product should be recorded as an AE. If the sequela of 
an overdose is an SAE, then the sequela must be reported on an SAE report form and as an AE. 
The overdose resulting in the SAE should be identified as the cause of the event on the SAE 
report form and eCRF but should not be reported as an SAE itself. 
 
Abnormal laboratory values or diagnostic test results constitute AEs only if it: 
 results in discontinuation from the study 
 requires treatment, modification/ interruption of study drug(s), or any other therapeutic 
intervention  
 or is judged to be of significant clinical importance, e.g., one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing condition  
 
Hospitalization for elective surgery or routine clinical procedures that are not the result of an AE (e.g., 
surgical insertion of central line) should not be recorded as an AE.  
 
Disease progression should not be recorded as an AE, unless it is attributable to the study regimen by 
the site investigator. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 33 of 45 
 Serious Adverse Event (SAE) 
An SAE is any adverse event that: 
 Results in death. NOTE: Death due to disease progression should not be reported as a SAE, 
unless it is attributable by the site investigator to the study drug(s) 
 Is life-threatening (defined as an event in which the subject was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it were more 
severe) 
 Requires inpatient hospitalization for >24 hours or prolongation of existing hospitalization. 
NOTE: Hospitalization for anticipated or protocol specified procedures such as administration 
of chemotherapy, central line insertion, metastasis interventional therapy, resection of primary 
tumor, or elective surgery, will not be considered serious adverse events. 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly or birth defect 
 Is an important medical event (defined as a medical event(s) that may not be immediately life-
threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention (e.g., medical, 
surgical) to prevent one of the other serious outcomes listed in the definition above. Examples of 
such events include, but are not limited to, intensive treatment in an emergency room or at home 
for allergic bronchospasm; blood dyscrasias or convulsions not resulting in hospitalization; or the 
development of drug dependency or drug abuse. 
 
Events not considered to be SAEs are hospitalizations for: 
 A standard procedure for protocol therapy administration. However, hospitalization or prolonged 
hospitalization for a complication of therapy administration will be reported as an SAE. 
 Routine treatment or monitoring of the studied indication not associated with any deterioration in 
condition. 
 The administration of blood or platelet transfusion as routine treatment of studied Indication.  
However, hospitalization or prolonged hospitalization for a complication of such transfusion 
remains a reportable SAE. 
 A procedure for protocol/disease-related investigations (e.g., surgery, scans, endoscopy, 
sampling for laboratory tests, bone marrow sampling).  However, hospitalization or prolonged 
hospitalization for a complication of such procedures remains a reportable SAE. 
 Hospitalization or prolongation of hospitalization for technical, practical, or social reasons, in 
absence of an AE. 
 A procedure that is planned (i.e., planned prior to starting of treatment on study); must be 
documented in the source document and the CRF.  Hospitalization or prolonged hospitalization 
for a complication remains a reportable SAE. 
 An elective treatment of or an elective procedure for a pre-existing condition unrelated to the 
studied indication. 
 Emergency outpatient treatment or observation that does not result in admission, unless fulfilling 
other seriousness criteria above. 
 Unexpected Adverse Event 
For this study, an AE is considered unexpected when it varies in nature, intensity or frequency from 
information provided in the current IB, package insert or when it is not included in the informed consent 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 34 of 45 
document as a potential risk. Unexpected also refers to AEs that are mentioned in the IB as occurring 
with a class of drugs or are anticipated from the pharmacological properties of the drug, but are not 
specifically mentioned as occurring with the particular drug under investigation.   
 Causality  
AEs will be categorized according to the likelihood that they are related to the study drug(s). 
Specifically, they will be categorized using the following terms:  
Not suspected: Means a causal relationship of the adverse event to IP administration is unlikely or 
unrelated, or other medications, therapeutic interventions, or underlying conditions provide a sufficient 
explanation for the observed event. 
Unrelated 
The Adverse Event is clearly not related to the drug(s)  
Unlikely 
The Adverse Event is doubtfully related to the drug(s)  
 
Suspected: Means there is a reasonable possibility (possible, probable, definite) that the administration 
of IP caused the adverse event. ‘Reasonable possibility’ means there is evidence to suggest a causal 
relationship between the IP and the adverse event. 
Possible 
The Adverse Event may be related to the drug(s)  
Probable 
The Adverse Event is likely related to the drug(s)  
Definite 
The Adverse Event is clearly related to the drug(s)  
 
Reporting 
 Adverse Events 
 AEs will be recorded from time of signed informed consent until 30 days after discontinuation of 
study drug(s).  
 AEs will be recorded regardless of whether or not they are considered related to the study 
drug(s).   
 All AEs will be recorded in the subject’s medical record and on the appropriate study specific 
eCRF form within OnCore. 
 AEs considered related to study drug(s) will be followed until resolution to ≤ Grade 1 or 
baseline, deemed clinically insignificant, and/or until a new anti-cancer treatment starts, 
whichever is earlier. 
 Serious Adverse Events (SAEs) 
 
Site Requirements for Reporting SAEs to Big Ten CRC Administrative Headquarters 
 SAEs will be reported from time of signed informed consent until 30 days after discontinuation 
of study drug(s) and those SAEs made known to the investigator at any time thereafter that are 
suspected of being related to the study drug(s).  
 SAEs will be reported on the SAE Submission Form within 24 hours of discovery of the event.   
 SAEs include events related and unrelated to the study drug(s).  

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 35 of 45 
 All SAEs will be recorded in the subject’s medical record and on the appropriate study specific 
eCRF form within OnCore.   
 All SAEs regardless of relation to study drug will be followed until resolution to ≤ Grade 1 or 
baseline and/or deemed clinically insignificant and/or until a new anti-cancer treatment starts, 
whichever occurs first. 
 
The completed SAE Submission Form must be submitted to Big Ten CRC AHQ within 24 hours of 
discovery of the event. The form may be submitted to Big Ten CRC AHQ electronically to 
safety@hoosiercancer.org. The site investigator is responsible for informing the IRB and/or other local 
regulatory bodies as per local requirements.   
 
The original copy of the SAE Submission Form and the email correspondence must be kept within the 
study file at the study site. 
 
Once the SAE has resolved (see resolution guidelines above), sites must electronically submit a follow-
up SAE Submission Form within a reasonable timeframe to Big Ten CRC AHQ at 
safety@hoosiercancer.org. 
 
Big Ten CRC AHQ Requirements for Reporting SAEs to Celgene Corporation  
Expedited Reporting by Big Ten CRC to Celgene 
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events 
of being related to nab-paclitaxel based on the Investigator Brochure.  In the United States, all suspected 
unexpected serious adverse reactions (SUSARs) will be reported in an expedited manner in accordance 
with 21 CFR 312.32. 
 
Serious adverse events (SAE) are defined above. Big Ten CRC must inform Celgene in writing using a 
SAE Submission Form of any SAE within 24 hours of being aware of the event.  The written report 
must be completed and supplied to Celgene by facsimile within 24 hours.  The initial report must be as 
complete as possible, including an assessment of the causal relationship between the event and the 
investigational product(s).  Information not available at the time of the initial report (e.g., an end date for 
the adverse event or laboratory values received after the report) must be documented on a follow-up 
report.  A final report to document resolution of the SAE is required.  The Celgene tracking number 
(AX-CL-GAS-PI-006239) and the institutional protocol number (BTCRC-GI15-015) should be included 
on SAE reports (or on the fax cover letter) sent to Celgene.  A copy of the fax transmission confirmation 
of the SAE report to Celgene should be attached to the SAE and retained with the study records. 
 
Drug Safety Contact Information: 
Celgene Corporation 
Global Drug Safety and Risk Management 
556 Morris Avenue, Building S12 
Summit, New Jersey 07901 
Fax: (908) 673-9115 
E-mail: drugsafety@celgene.com 
Telephone: 1-908-673-9667 
Toll Free:    1-800-640-7854 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 36 of 45 
 
Sponsor-Investigator Responsibilities to Big Ten CRC AHQ 
Big Ten CRC AHQ will send an SAE summary to the sponsor-investigator within 1 business day of 
receipt of SAE Submission Form from a site.  The sponsor-investigator will promptly review the SAE 
summary and assess for expectedness and relatedness. 
 
Big Ten CRC AHQ Requirements for Reporting SAEs to FDA 
The FDA has concluded that this protocol is exempt from the requirements of an IND. Big Ten CRC 
AHQ will continue to facilitate compliance of applicable requirements for the sponsor-investigator in 
relation to this study. This includes but is not limited to 21CFR50.20 informed consent, 21CFR Part 56 
IRB, and pertinent sections of the Public Health Service Act and FDAAA. 
 Reporting Pregnancies 
Pregnancies and suspected pregnancies (including a positive pregnancy test, regardless of age or disease 
state) of a female subject occurring while the subject is on IP, or within 30 days of the subject’s last dose 
of IP, are considered immediately reportable events.  IP is to be discontinued immediately and the 
pregnancy, suspected pregnancy, or positive pregnancy test must be reported immediately. The female 
subject should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for 
further evaluation and counseling. 
 
Male Subjects 
If a female partner of a male subject taking investigational product becomes pregnant, the male subject 
taking IP should notify the Site Investigator, and the pregnant female partner should be advised to call 
their healthcare provider immediately. Male patients treated with nab-paclitaxel are advised not to 
father a child during and up to 6 months after treatment. 
 
Site Requirements for Reporting Pregnancies to Big Ten CRC Administrative Headquarters 
The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to Big Ten CRC AHQ 
immediately. 
 
The Site Investigator will follow the female subject until completion of the pregnancy and must notify 
Big Ten CRC AHQ immediately about the outcome of the pregnancy (either normal or abnormal 
outcome).  
 
If the outcome of the pregnancy meets any of the serious criteria (including spontaneous or therapeutic 
abortion, fetal and neonatal death or congenital anomaly), it must be reported as an SAE. Any death of 
an infant which occurs in connection with in utero exposure to the Study Drug within 28 days of birth 
must be reported as SAEs. In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported immediately. The Investigator will also 
document any congenital anomaly detected in an aborted fetus.  
 
Send reports to Big Ten CRC AHQ by emailing the Celgene Pregnancy Reporting Form or SAE 
Submission Form to safety@hoosiercancer.org within 24 hours of the Investigator’s knowledge of the 
event. 
 
Big Ten CRC AHQ Requirements for Reporting Pregnancies to Celgene Corporation 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 37 of 45 
Big Ten CRC AHQ will submit all pregnancy reports received from sites to Celgene within 24 hours of 
receipt of the Celgene Pregnancy Reporting Form or SAE Submission Form. The Celgene tracking 
number (AX-CL-GAS-PI-006239) and the institutional protocol number (BTCRC-GI15-015) should be 
included on report (or on the fax cover letter) sent to Celgene. 
 
Big Ten CRC AHQ will submit all pregnancy reports and any other relevant safety information to: 
 
Drug Safety Contact Information: 
Celgene Corporation 
Global Drug Safety and Risk Management 
556 Morris Avenue, Building S12 
Summit, New Jersey 07901 
Fax: (908) 673-9115 
E-mail: drugsafety@celgene.com 
Telephone: 1-908-673-9667 
Toll Free:    1-800-640-7854 
 
Follow-up information will be provided to Celgene as reasonably requested. 
 
IND Safety Reports Unrelated to this Trial 
Celgene will provide IND safety reports from external studies that involve the study drug(s) per their 
guidelines to Big Ten CRC AHQ. Big Ten CRC AHQ will forward safety reports to the sponsor-
investigator who will review these reports and determine if revisions are needed to the protocol or 
consent. Big Ten CRC AHQ will forward these reports to participating sites within 1 business day of 
receiving sponsor-investigator’s review.  Based on sponsor-investigator’s review, applicable changes 
will be made to protocol and informed consent document (if required).  All IND safety reports will also 
be made available to sites via the EDC system. 
 
Upon receipt from Big Ten CRC AHQ, site investigators (or designees) are responsible for submitting 
these safety reports to their respective IRBs, as per their IRB policies. 
 
IND safety reports determined by the sponsor-investigator to be serious, unexpected, and possibly 
related (UPIRSO) will also be submitted to the Northwestern DMC for review 
(croqualityassurance@northwestern.edu). 
12. 
STATISTICAL METHODS 
 
Endpoints 
Endpoints are described in Section 2.2 and include the primary endpoint which is the objective response 
rate (partial or complete response). All subjects with measurable disease who have received at least one 
cycle of treatment and have their disease re-evaluated will be evaluable for assessment of objective 
response.  Secondary endpoints include overall survival, progression-free survival, time to progression 
and disease control rate.  Safety endpoints include toxicities.   

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 38 of 45 
 
Sample Size and Accrual  
A Simon [1989] optimal two-stage design [16] will be employed. A 5% response rate precludes further 
study whereas a 20% response rate would indicate that further investigation of the treatment is 
warranted (i.e., P0=0.05 and P1=0.20 in the Simon terminology). Using α and β errors of 0.10 and 0.10, 
respectively, 12 patients will be enrolled in the first stage and if no responses are observed, the trial will 
be terminated. Otherwise, an additional 27 patients will be enrolled in the second stage and if ≤ 3 
responses are observed among the 39 patients, the agent will not be considered worthy of further testing; 
whereas, if 4 or more responses are observed the drug will be considered sufficiently active to justify 
further study. This design has 90% power under the alternative hypothesis and provides a 54% 
probability of early stopping if the true response rate is only 5%. The baseline of ORR probability is 
based on existing data from a couple of platinum -5-FU combinations phase II, TTT trials with a 
minimum ORR of 16% [6-8, 24-31]. 
 
A maximum of 39 patients will be enrolled to attain 37 eligible/evaluable patients (total target sample 
size has been inflated by 5% to allow for patient ineligibility/inevaluability). Patients will be followed 
until the minimum of the time to progression, time to death before the patient’s data will be included in 
the decision rule. 
 
Analysis Datasets 
 
Population 
Definition 
Enrolled 
This will comprise all subjects who meet the eligibility 
criteria and are registered onto the study.  
Evaluable 
This will comprise all subjects who receive at least one 
dose of trial drug and either undergo at least one post-
baseline assessment or die before any evaluation.   
Intention-to-treat (ITT) 
This will comprise all subjects who meet the eligibility 
criteria and are registered onto the study irrespective of 
their compliance to the planned course of treatment. (See 
IIT principle below*). 
Per Protocol Set (Valid 
Cases, Efficacy 
Sample, Evaluable 
Subjects Sample) 
This will comprise all subjects who complied with the 
protocol sufficiently to ensure that these data would be 
likely to exhibit the effects of treatment, according to the 
underlying scientific model. Compliance covers such 
considerations as exposure to treatment, availability of 
measurements and absence of major protocol violations. 
This population should be specifically defined in the 
protocol. 
Safety 
This will comprise all subjects that contribute data to the 
safety analysis.  This population should be specifically 
defined in the protocol.  
Treated 
This will comprise all subjects who have been exposed to 
the planned course of treatment to any extent. 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 39 of 45 
 
*IIT Principle - The principle that asserts that the effect of a treatment policy can be best assessed by 
evaluating on the basis of the intention to treat a subject with the planned treatment regimen rather than 
on the basis of the actual treatment given.  
 
 
Assessment of Safety 
Any subject who receive at least one dose of treatment will be evaluable for toxicity. Safety will be 
evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE), version 4.   
 
In addition to continuous monitoring of adverse events through expedited reporting and routine 
tabulations of toxicities being reported through case report forms, the trial will include two formal 
evaluations of toxicity before the completion of accrual. It is expected that the true proportion of any 
grade 3 or higher treatment-related adverse event (exclusive of hematologic toxicity, nausea/vomiting, 
fatigue, alopecia and liver function abnormalities) will be no higher than 30% in this patient population 
(most events would be expected to have true rates quite lower than 30%). True proportions higher than 
30% would be reason to evaluate the regimen for possible modification. Given these assumptions, the 
following plan will be followed.  
 
After 10 patients have been treated through at least 2 cycles, all treatment-related adverse event 
information will be compiled and tabulated by toxicity grade. If any observed grade 3 or higher 
treatment-related adverse event proportion (exclusive of hematologic toxicity, nausea/vomiting, fatigue, 
alopecia and liver function abnormalities) is higher than 40% (4 or more out of 10 patients), a detailed 
review of all treatment-related adverse events will be conducted and the study team may decide that 
treatment modification is necessary. If the true proportion of any adverse event is 50% (or higher) there 
is at least 87% probability of exceeding the observed adverse event boundary whereas if the true 
proportion is 30% there is only 11% probability of crossing the toxicity boundary. The above decision 
boundary (40% or more observed events) will be followed for grade 4 or higher toxicities in the above 
exclusion list (hematologic toxicity, nausea/vomiting, fatigue, alopecia and liver function abnormalities) 
in order to evaluate those events that might be expected to have relatively high event rates at grade 3, but 
not at grade 4. 
 
Data Analysis Plan.  
Analyses will be performed for all patients having received at least one dose of study drug after the first 
and second stage of the study. Response rate and disease control rate and their 95% confidence intervals 
will be estimated using exact binomial methods.  Safety data summaries will describe the incidence of 
adverse events (including severity and relationship to drug or treatment), serious adverse events, adverse 
events leading to early withdrawal or death, and Grade 3 or 4 toxicities.  Median duration of response and 
its 95% confidence interval will be calculated.  Kaplan-Meier curves will be used to summarize the time-
to-event endpoints of PFS and OS.  All event times will be calculated relative to the start of FOLFOX-A 
combination.  Distributions of PFS, TTP and OS will be estimated using the method of Kaplan-Meier [17] 
and univariate testing will be done via the log rank test [18]. Descriptive statistics will be performed for 
all on-study and clinical-demographic data. Chi-square or Fisher’s exact tests will be used as appropriate 
for categorical associations and Wilcoxon rank tests or t-tests for continuous measures. All event times 
will be calculated relative to the start date of the study drug combination. ORR and DCR will be 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 40 of 45 
summarized by count and percent of subjects with each ordinal response analyzed by Cochran-Mantel-
Hanzel test [19] for comparison between groups. Correlation of change in CA 19-9 to ORR, PFS, TTP, 
DCR and OS will be completed as described above. Binary outcome regression modeling will be 
accomplished via standard logistic regression and time-to-event models (which will be largely 
exploratory) will be done using the Cox proportional hazards model. The safety data summaries will 
describe the incidence of adverse events (including severity and relationship to drug or treatment), serious 
adverse events and those leading to early withdrawal or death, as well as grade 3 or 4 toxicities. These 
analyses will be largely descriptive. Efficacy and safety analyses will be completed by intention to treat. 
Statistical analyses will be completed using SAS®. 
 
13. 
TRIAL MANAGEMENT 
 
Data and Safety Monitoring  
The Data Monitoring Committee (DMC) of the Robert H. Lurie Comprehensive Cancer Center will 
provide study oversight activities for this study. They will review and monitor study progress, toxicity, 
safety, and other data from this trial.  Questions about subject safety or protocol performance will be 
addressed with the sponsor-investigator, statistician, and study team members. Should any major 
concerns arise; the DMC will offer recommendations regarding whether or not to suspend the trial.   
Big Ten CRC AHQ must submit all SAEs to the Quality Assurance Managers (QAMs) in real time, as 
defined below. 
 Big Ten CRC AHQ will compile data summary reports for this trial and submit these reports 
monthly to the sponsor-investigator.   
 Big Ten CRC AHQ will report all SAEs to the DMC Quality Assurance (QA) office within 
one business day of receipt and formally present them at each DMC meeting. 
 Submit data summary reports to the lead institution DMC and attend DMC reviews: 
o as applicable, following any new reports of protocol deviations or SAEs, or, if 
overall study data delinquency that exceeds 10% incomplete forms or sites with 
data delinquency that are not responding sufficiently to the Big Ten CRC AHQ 
data delinquency escalation process   
o throughout the study, semi-annual comprehensive DMC review  
Any data set the PI wants to use to publish the trial will be presented to and approved by the 
DMC. 
 Data Safety Monitoring Committee 
The Northwestern DSMC will review the following: 
 Adverse event summary report 
 Monitoring and/or audit reports as applicable 
 Study accrual pattern  
 Data delinquency 
 Protocol deviations 
 
The Robert H. Lurie Comprehensive Cancer Center’s DMC will conduct a comprehensive study review 
semi-annually. Documentation of DMC reviews will be provided to sponsor-investigator and Big Ten 
CRC AHQ. Issues of immediate concern by the DSMC are brought to the attention of the sponsor-

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 41 of 45 
investigator (and other regulatory bodies as appropriate) and a formal response from the sponsor-
investigator is requested.   
 
Data Quality Oversight Activities 
Remote validation of OnCore data will be completed on a continual basis throughout the life cycle of the 
study.  A summary report (QC Report) of these checks together with any queries resulting from manual 
review of the eCRFs will be generated for each site and transmitted to the site and the site monitor. 
Corrections will be made by the study site personnel. 
 
If at any time, Big Ten CRC AHQ or the sponsor-investigator determines a site is not compliant with 
recording and reporting of data, a “for-cause” audit will be initiated. 
 
Monitoring visits to the trial sites may be made periodically during the trial to ensure key aspects of the 
protocol are followed. For-cause visits may occur as necessary. During an onsite visit, source documents 
will be reviewed for verification of agreement with data entered into OnCore.  It is important for the site 
investigator and their relevant personnel to be available for a sufficient amount of time during the 
monitoring visits or audit, if applicable. The site investigator and institution guarantee access to source 
documents by Big Ten CRC AHQ or its designee. 
 
The trial site may also be subject to quality assurance audit by Celgene or its designee as well as 
inspection by appropriate regulatory agencies. 
 
Amendments 
If it is necessary for the study protocol to be amended and/or the informed consent revised, the 
amendment or a new version of the study protocol (amended protocol) and/or the revised informed 
consent will be generated by Big Ten CRC AHQ and must be approved by the sponsor-investigator, 
Celgene, and each site’s IRB.  
 
The site investigator is responsible for the distribution of these documents to his or her IRB, and to the 
staff at his or her center. 
 
Compliance with Trial Registration and Results Posting Requirements 
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the Food and 
Drug Administration Amendments Act (FDAAA), the sponsor-investigator of the trial is solely 
responsible for determining whether the trial and its results are subject to the requirements for 
submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov. The sponsor-investigator has 
delegated responsibility to Big Ten CRC AHQ for registering the trial and posting the results on 
clinicaltrials.gov. Information posted will allow subjects to identify potentially appropriate trials for 
their disease conditions and pursue participation by calling a central contact number for further 
information on appropriate trial locations and study site contact information. 
 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 42 of 45 
14. 
DATA HANDLING AND RECORD KEEPING 
 
Data Management 
Big Ten CRC AHQ will serve as the Clinical Research Organization for this trial. Data will be collected 
through a web-based clinical research platform, OnCore, a system compliant with Good Clinical 
Practices and Federal Rules and Regulations. Other study institutions will be given a password to 
directly enter their own data onto the web site via electronic case report forms (eCRFs). Big Ten CRC 
AHQ personnel will coordinate and manage data for quality control assurance and integrity. 
 
All data will be collected and entered into OnCore by study site personnel from participating institutions.   
 
Case Report Forms and Submission 
Generally, clinical data will be electronically captured in OnCore. If procedures on the study calendar 
are performed for standard of care, at minimum, that data will be captured in the source document. 
Select standard of care data will also be captured in OnCore, according to study-specific objectives. 
Please see the Data and Safety Oversight Process (DSOP) guidelines for further details.  
 
The completed dataset is housed at Big Ten CRC AHQ and is the sole property of the sponsor-
investigator’s institution. It should not be made available in any form to third parties, except for 
authorized representatives of appropriate Health/Regulatory Authorities, without written permission 
from the sponsor-investigator and Big Ten CRC AHQ. After the initial publication, the complete data 
set will be available to all Big Ten CRC institutions. 
Trials that use the Lurie Cancer’s DSMP are not permitted to publish trial data in any capacity until the 
data has been approved by the DMC.  If a PI anticipates that he or she will publish data prior to three 
months after the Clinicaltrials.gov primary completion date, they must notify the assigned QAM as soon 
as possible.  QAMs can prepare the data summary for DMC approval upon PI request, but must have a 
minimum six weeks’ notification. 
 
Record Retention 
To enable evaluations and/or audits from Health Authorities/ Big Ten CRC AHQ, the site investigator 
agrees to keep records, including the identity of all subjects (sufficient information to link records; e.g., 
hospital records), all original signed informed consent forms, copies of all source documents, and 
detailed records of drug disposition.  All source documents are to remain in the subject’s file and 
retained by the site investigator in compliance with the site contract with Big Ten CRC AHQ. No 
records will be destroyed until Big Ten CRC AHQ confirms destruction is permitted. 
 
Confidentiality 
There is a slight risk of loss of confidentiality of subject information.  All records identifying the 
subjects will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, 
will not be made publicly available. Information collected will be maintained on secure, password 
protected electronic systems. Paper files that contain personal information will be kept in locked and 
secure locations only accessible to the study site personnel.  
 
Subjects will be informed in writing that some organizations, including the sponsor-investigator and 
his/her research associates, Big Ten CRC AHQ, Celgene, IRB, or government agencies like the FDA, 
may inspect their medical records to verify the information collected, and that all personal information 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 43 of 45 
made available for inspection will be handled in strictest confidence and in accordance with local data 
protection laws. 
 
If the results of the study are published, the subjects’ identity will remain confidential. 
15. 
ETHICS 
 
Institutional Review Board (IRB) Approval 
The final study protocol and the final version of the informed consent form must be approved in writing 
by an IRB.  The site investigator must submit written approval by the IRB to Big Ten CRC AHQ before 
he or she can enroll subjects into the study.  
 
The site investigator is responsible for informing the IRB of any amendment to the protocol in 
accordance with local requirements. In addition, the IRB must approve all advertising used to recruit 
subjects for the study. The protocol must be re-approved by the IRB as local regulations require.  
 
Progress reports and notifications of adverse events will be provided to the IRB according to local 
regulations and guidelines. 
 
Ethical Conduct of the Study 
The study will be performed in accordance with ethical principles originating from the Declaration of 
Helsinki. Conduct of the study will be in compliance with ICH Good Clinical Practice, and with all 
applicable federal (including 21 CFR parts 56 & 50), state, or local laws. 
 
Informed Consent Process 
The site investigator will ensure the subject is given full and adequate oral and written information about 
the nature, purpose, possible risks and benefits of the study.  Subjects must also be notified they are free 
to discontinue from the study at any time.  The subject should be given the opportunity to ask questions 
and allowed time to consider the information provided. 
 
The subject’s signed and dated informed consent must be obtained before conducting any procedure 
specifically for the study.  The site investigator must store the original, signed informed consent form.  
A copy of the signed informed consent form must be given to the subject. 
 
 

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 44 of 45 
16. 
REFERENCES 
 
1. 
Aprile, G., et al., Metastatic gastric cancer in the last two decades: goals achieved and future 
promises. Future Oncol, 2015. 
2. 
Glimelius, B., et al., Randomized comparison between chemotherapy plus best supportive care 
with best supportive care in advanced gastric cancer. Ann Oncol, 1997. 8(2): p. 163-8. 
3. 
Wagner, A.D., et al., Chemotherapy in advanced gastric cancer: a systematic review and meta-
analysis based on aggregate data. J Clin Oncol, 2006. 24(18): p. 2903-9. 
4. 
Dicken, B.J., et al., Gastric adenocarcinoma: review and considerations for future directions. 
Ann Surg, 2005. 241(1): p. 27-39. 
5. 
Van Cutsem, E., et al., Phase III study of docetaxel and cisplatin plus fluorouracil compared 
with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the 
V325 Study Group. J Clin Oncol, 2006. 24(31): p. 4991-7. 
6. 
Cunningham, D., et al., Capecitabine and oxaliplatin for advanced esophagogastric cancer. N 
Engl J Med, 2008. 358(1): p. 36-46. 
7. 
Al-Batran, S.E., et al., Phase III trial in metastatic gastroesophageal adenocarcinoma with 
fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft 
Internistische Onkologie. J Clin Oncol, 2008. 26(9): p. 1435-42. 
8. 
Popov, I., et al., Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil 
and leucovorin in patients with advanced gastric cancer. J BUON, 2008. 13(4): p. 505-11. 
9.  
Sparreboom, A., et al., Cremophor EL-mediated alteration of paclitaxel distribution in human 
blood: clinical pharmacokinetic implications. Cancer Res, 1999. 59(7): p. 1454-7.  
10. 
 Desai, N., et al., Increased antitumor activity, intratumor paclitaxel concentrations, and 
endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with 
cremophor-based paclitaxel. Clin Cancer Res, 2006. 12(4): p. 1317-24.  
11. 
 Desai, N.P., et al., Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel 
versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC 
status. Anticancer Drugs, 2008. 19(9): p. 899-909.  
12.  
Guarneri, V., et al., Enhancing intracellular taxane delivery: current role and perspectives of 
nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin 
Pharmacother. 13(3): p. 395-406.  
13. 
 Gianni, L., et al., Nonlinear pharmacokinetics and metabolism of paclitaxel and its 
pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol, 1995. 13(1): p. 180-
90.  
14.  
Ait-Oudhia, S., et al., Meta-analysis of nanoparticulate paclitaxel delivery system 
pharmacokinetics and model prediction of associated neutropenia. Pharm Res, 2012. 29(10): p. 
2833-44. 
15. 
Gradishar, W.J., et al., Phase III trial of nanoparticle albumin-bound paclitaxel compared with 
polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 2005. 
23(31): p. 7794-803. 
16. 
 Simon, R., Optimal two-stage designs for phase II clinical trials. Control Clin Trials, 1989. 
10(1): p. 1-10.  
17. 
Kaplan, E.L. and P. Meier, Nonparametric Estimation from Incomplete Observations. Journal of 
the American Statistical Association, 1958. 53(282): p. 457-481.  
18. 
 Mantel, N., Evaluation of survival data and two new rank order statistics arising in its 
consideration. Cancer Chemother Rep, 1966. 50(3): p. 163-70.  

Big Ten Cancer Research Consortium 
 
 
Clinical Study Protocol 
 
 
 
 
BTCRC-GI15-015 
15FEB2021 
Confidential 
Page 45 of 45 
19. 
 Mantel, N. and W. Haenszel, Statistical aspects of the analysis of data from retrospective studies 
of disease. J Natl Cancer Inst, 1959. 22(4): p. 719-48. 
20 
Illei, P., et al., SPARC Expression in Pancreatic Adenocarcinoma: Development of a Robust, 
Predictive Immunohistochemical Assay and Scoring Method. Mod Pathol 26:422-433, 2013. 
21.  
Trieu, V., et al., (2007). Nanoparticle Albumin-bound (nab) technology may enhance antitumor 
activity via targeting of SPARC protein. In: New Targets and Delivery System for Cancer 
Diagnosis and Treatment (SKCC), San Diego, CA. Abstract 53.  
22. 
[Removed] 
23.  
Neesse, A., et al., SPARC independent drug delivery and antitumour effects of nab-paclitaxel in 
genetically engineered mice. Gut Published Online First: [3rd September 2013] doi: 
10.1136/gutjnl-2013-305559.  
24. 
Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II 
stidu of three standard chemotherapy regimens (SCF, IC, FOLFOX) plus cetuximab in metastatic 
esophageal and GE junction cancer (Abstract 4006). J Clin Oncol 2010; 28:302s. 
25. 
Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional 
fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 
2004; 22:658.  
26. 
 Jatoi A, Murphy BR, Foster NR, et al. Oxaliplatin and capecitabine in patients with metastatic 
adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study 
from the North Central Cancer Treatment Group. Ann Oncol 2006; 17:29.  
27. 
Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly 
oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 2006; 
94:959. 
28.  
Neri B, Pantaleo P, Giommoni E, et al. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as 
first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer 2007; 96:1043.  
29. 
Liu ZF, Guo QS, Zhang XQ, et al. Biweekly oxaliplatin in combination with continuous 
infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line 
chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 2008; 31:259.  
30. 
Wang J, Chang J, Yu H, et al. A phase II study of oxaliplatin in combination with leucovorin and 
fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of 
esophagus. Cancer Chemother Pharmacol 2013; 71:905. 
31. 
Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to 
cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. 
Gastric Cancer 2011; 14:50.